View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Mar. 03, 2017	Jun. 30, 2016
Document Entity Information [Abstract]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		120,982,543
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 297,436,243

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 9,569	$ 15,577
Receivables, less allowance for doubtful accounts of $44,730 and $59,689 at December 31, 2016 and 2015, respectively	111,811	97,353
Inventory	36,165	42,983
Prepaid expenses and other current assets	18,507	27,772
Total current assets	176,052	183,685
Property and equipment, net	32,535	31,939
Goodwill	365,947	308,729
Intangible assets, net	31,043	5,128
Other non-current assets	2,163	1,161
Total assets	607,740	530,642
Current liabilities
Current portion of long-term debt	18,521	24,380
Accounts payable	59,134	65,077
Amounts due to plan sponsors	3,799	3,491
Accrued interest	6,705	6,898
Accrued expenses and other current liabilities	42,191	52,918
Total current liabilities	130,350	152,764
Long-term debt, net of current portion	433,413	393,741
Deferred taxes	2,281	236
Other non-current liabilities	1,257	1,861
Total liabilities	567,301	548,602
Stockholders’ (deficit) equity
Preferred stock, $.0001 par value; 5,000,000 and 4,175,000 shares authorized; no shares issued and outstanding as of December 31, 2016 and 2015, respectively	0	0
Common stock, $.0001 par value; 250,000,000 and 125,000,000 shares authorized; 117,682,543 and 71,421,664 shares issued; and 117,682,543 and 68,767,613 shares outstanding as of December 31, 2016 and 2015, respectively	12	8
Treasury stock, no shares outstanding as of December 31, 2016 and 2,654,051 shares outstanding, at cost, as of December 31, 2015	0	(10,737)
Additional paid-in capital	611,844	531,764
Accumulated deficit	(643,419)	(601,913)
Total stockholders’ (deficit) equity	(31,563)	(80,878)
Total liabilities and stockholders’ (deficit) equity	607,740	530,642
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 and 635,822 shares issued and outstanding as of December 31, 2016 and 2015, respectively; and, $2,603 and $69,702 liquidation preference as of December 31, 2016 and 2015, respectively
Current liabilities
Convertible preferred stock	2,462	62,918
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding; and $75,491 liquidation preference as of December 31, 2016
Current liabilities
Convertible preferred stock	$ 69,540	$ 0

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Allowance for doubtful accounts	$ 44,730	$ 59,689
Preferred stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	4,175,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	125,000,000
Common stock, shares issued (in shares)	117,682,543	71,421,664
Common stock, shares outstanding (in shares)	117,682,543	68,767,613
Treasury stock (in shares)	0	2,654,051
Series A Preferred Stock
Convertible preferred stock series, par value (in USD per share)	$ 0.0001	$ 0.0001
Convertible preferred stock series, shares authorized (in shares)	825,000	825,000
Convertible preferred stock series, shares issued (in shares)	21,645	635,822
Convertible preferred stock series, shares outstanding (in shares)	21,645	635,822
Convertible preferred stock series, liquidation preference	$ 2,603	$ 69,702
Series C Preferred Stock
Convertible preferred stock series, par value (in USD per share)	$ 0.0001
Convertible preferred stock series, shares authorized (in shares)	625,000
Convertible preferred stock series, shares issued (in shares)	614,177
Convertible preferred stock series, shares outstanding (in shares)	614,177
Convertible preferred stock series, liquidation preference	$ 75,491

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net revenue	$ 935,589	$ 982,223	$ 922,654
Cost of revenue (excluding depreciation expense)	669,958	721,308	671,901
Gross profit	265,631	260,915	250,753
Other operating expenses	170,718	165,998	166,552
Bad debt expense	26,799	41,042	79,547
General and administrative expenses	39,225	42,524	49,314
Change in fair value of equity linked liabilities	(10,450)	0	0
Impairment of goodwill	0	251,850	0
Restructuring, acquisition, integration, and other expenses, net	15,859	24,405	30,206
Depreciation and amortization expense	21,551	22,743	22,943
Interest expense	38,235	37,313	40,918
Gain on dispositions	(3,954)	0	0
Loss from continuing operations, before income taxes	(32,352)	(324,960)	(138,727)
Income tax provision (benefit)	2,015	(21,532)	11,193
Loss from continuing operations, net of income taxes	(34,367)	(303,428)	(149,920)
(Loss) income from discontinued operations, net of income taxes	(7,139)	3,721	2,452
Net loss	(41,506)	(299,707)	(147,468)
Accrued dividends on preferred stock	(8,392)	(6,120)	0
Deemed dividends on preferred stock	(692)	(3,690)	0
Loss attributable to common stockholders	$ (50,590)	$ (309,517)	$ (147,468)
Loss per common share:
Loss from continuing operations, basic and diluted (in USD per share)	$ (0.46)	$ (4.56)	$ (2.19)
(Loss) Income from discontinued operations, basic and diluted (in USD per share)	(0.08)	0.05	0.04
Net loss, basic and diluted (in USD per share)	$ (0.54)	$ (4.51)	$ (2.15)
Weighted average common shares outstanding, basic and diluted (in shares)	93,740	68,710	68,476

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2013	$ 354,583	$ 7	$ (10,311)	$ 519,625	$ (154,738)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	1,468	1		1,467
Surrender of stock to satisfy minimum tax withholding	(368)		(368)
Compensation under employee stock compensation plans	8,590			8,590
Net loss	(147,468)				(147,468)
Ending Balance at Dec. 31, 2014	216,805	8	(10,679)	529,682	(302,206)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	2	0		2
Surrender of stock to satisfy minimum tax withholding	(58)		(58)
Issuance of Series A convertible preferred stock and warrants	6,581			6,581
Accrued dividends on preferred stock	(6,120)			(6,120)
Deemed dividends on preferred stock	(3,690)			(3,690)
Compensation under employee stock compensation plans	5,309			5,309
Net loss	(299,707)				(299,707)
Ending Balance at Dec. 31, 2015	(80,878)	8	(10,737)	531,764	(601,913)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net proceeds of public stock offering	83,267	4		83,263
Surrender of stock to satisfy minimum tax withholding	(33)		(33)
Surrender of stock - settlement	0		(255)	255
Shares issued in connection with the acquisition of Home Solutions, Inc.	9,937		11,025	(1,088)
Value of equity linked liabilities reclassified to equity upon approval of Charter Amendment	2,847			2,847
Accrued dividends on preferred stock	(8,392)			(8,392)
Deemed dividends on preferred stock	(692)			(692)
Compensation under employee stock compensation plans	3,887			3,887
Net loss	(41,506)				(41,506)
Ending Balance at Dec. 31, 2016	$ (31,563)	$ 12	$ 0	$ 611,844	$ (643,419)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (41,506)	$ (299,707)	$ (147,468)
Less: Income (loss) from discontinued operations, net of income taxes	(7,139)	3,721	2,452
Loss from continuing operations, net of income taxes	(34,367)	(303,428)	(149,920)
Adjustments to reconcile net loss from continuing operations to net cash (used in) operating activities:
Depreciation and amortization	21,551	22,743	22,943
Impairment of goodwill	0	251,850	0
Amortization of deferred financing costs and debt discount	4,042	3,440	4,153
Change in fair value of contingent consideration	(4,597)	(30)	(7,364)
Change in fair value of equity linked liabilities	(10,450)	0	0
Change in deferred income tax	2,045	(20,089)	9,359
Compensation under stock-based compensation plans	1,963	4,513	8,570
Gain on dispositions	(3,954)	0	0
Loss on extinguishment of debt	0	0	2,373
Changes in assets and liabilities, net of acquired businesses:
Receivables, net of bad debt expense	(2,502)	20,628	34,534
Inventory	10,016	(5,769)	(2,952)
Prepaid expenses and other assets	(892)	(4,003)	5,474
Accounts payable	(20,517)	(24,129)	27,092
Amounts due to plan sponsors	308	(1,377)	562
Accrued interest	(193)	44	4,681
Accrued expenses and other liabilities	2,344	(6,682)	7,310
Net cash used in operating activities from continuing operations	(35,203)	(62,289)	(33,185)
Net cash (used in) provided by operating activities from discontinued operations	(7,566)	(2,453)	1,769
Net cash used in operating activities	(42,769)	(64,742)	(31,416)
Cash flows from investing activities:
Cash consideration paid for acquisitions, net of cash acquired	(67,516)	0	(454)
Purchases of property and equipment, net	(9,642)	(11,544)	(13,829)
Proceeds from dispositions	4,177	0	0
Net cash proceeds from sale of unconsolidated affiliate	0	0	852
Net cash used in investing activities from continuing operations	(72,981)	(11,544)	(13,431)
Net cash provided by investing activities from discontinued operations	0	24,565	57,688
Net cash (used in) provided by investing activities	(72,981)	13,021	44,257
Cash flows from financing activities:
Net proceeds from equity offering, net of expenses and underwriter allotment	83,267	0	0
Proceeds from issuance of convertible preferred stock and warrants, net of issuance costs	0	59,691	0
Proceeds from senior notes due 2021, net of discount, lenders' fees and other expenses		0	194,539
Deferred and other financing costs	0	(2,630)	(1,135)
Borrowings on revolving credit facility	104,300	203,663	244,700
Repayments on revolving credit facility	(64,000)	(193,663)	(279,703)
Principal payments of long-term debt	(12,550)	0	(172,243)
Repayments of capital leases	(1,073)	(395)	(360)
Net proceeds from exercise of employee stock compensation plans	(202)	(108)	1,100
Net cash provided by (used in) financing activities	109,742	66,558	(13,102)
Net change in cash and cash equivalents	(6,008)	14,837	(261)
Cash and cash equivalents - beginning of period	15,577	740	1,001
Cash and cash equivalents - end of period	9,569	15,577	740
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	34,696	34,302	34,133
Cash paid during the period for income taxes, net of refunds	(372)	114	1,651
DISCLOSURE OF NON-CASH TRANSACTIONS:
Issuance of 3,750,000 shares in connection with the Home Solutions acquisition	9,938	0	0
Capital lease obligations incurred to acquire property and equipment	$ 2,314	$ 0	$ 107

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)	12 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)	Dec. 31, 2016 shares
Statement of Cash Flows [Abstract]
Shares issued in acquisition (in shares)	3,750,000

NATURE OF BUSINESS	12 Months Ended
NATURE OF BUSINESS	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	NATURE OF BUSINESS Corporate Organization and Business BioScrip, Inc. and subsidiaries (the “Company” or “BioScrip”) is a national provider of infusion service that partners with physicians, hospital systems, skilled nursing facilities and healthcare payors to provide patients access to post-acute care services. The Company operates with a commitment to bring customer-focused infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, the Company aims to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom it serves. The Company’s platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch, community-based and home-based care environment. The Company’s core services are provided in coordination with, and under the direction of, the patient’s physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Whether in the home, physician office, ambulatory infusion center, skilled nursing facility or other alternate sites of care, the Company provides products, services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure. On August 27, 2015, the Company completed the sale of substantially all of the Company’s Pharmacy Benefit Management Services segment (the “PBM Business”) to ProCare Pharmacy Benefit Manager Inc. (see Note 6 - Discontinued Operations). As a result of the sale of the PBM Business, the Company no longer has multiple operating segments. The change reflects how the Company's chief operating decision maker reviews the Company’s results in terms of allocating resources and assessing performance. Basis of Presentation The Company’s Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Reclassifications With the sale of the PBM Services segment (the “PBM Business”) in 2015 all prior period financial statements have been reclassified to include the PBM Business as discontinued operations, along with other reclassifications specific to vendor rebates and deferred financing costs.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation

The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value Measurements

The fair value measurement accounting standard, ASC Topic 820, Fair Value Measurement (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available.

The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:


•	Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.


•	Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.


•	Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents.

Receivables

Receivables include amounts due from government sources, such as Medicare and Medicaid programs, Managed Care Organizations and other commercial insurance; amounts due from patient co-payments; and service fees resulting from the distribution of certain drugs through retail pharmacies.

Allowance for Doubtful Accounts

The allowance for doubtful accounts is based on estimates of losses related to receivable balances. The risk of collection varies based upon the product, the payor (commercial health insurance and government) and the patient’s ability to pay the amounts not reimbursed by the payor. We estimate the allowance for doubtful accounts based on several factors including the age of the outstanding receivables, the historical experience of collections, adjusting for current economic conditions and, in some cases, evaluating specific customer accounts for the ability to pay. Collection agencies are employed and legal action is taken when we determine that taking collection actions is reasonable relative to the probability of receiving payment on amounts owed. Management judgment is used to assess the collectability of accounts and the ability of our customers to pay. Judgment is also used to assess trends in collections and the effects of systems and business process changes on our expected collection rates. The Company reviews the estimation process quarterly and makes changes to the estimates as necessary. When it is determined that a customer account is uncollectible, that balance is written off against the existing allowance.

Change in Estimate of the Collectability of Accounts Receivable

The Company experienced deterioration in the aging of certain accounts receivable in 2014 primarily due to delays and disruptions related to the integration of its acquisitions in 2013. As a result, the Company materially changed its estimates based on actual collection experience during and after the acquisition disruption period from 2014. The estimates were further revised during 2016 and had the effect of lowering our doubtful accounts allowance, overall, due to improved collection experience evidenced by more predictable cash receipts from our payors.

We believe we are adequately reserved on accounts receivable balances over 180 days; however, there is a higher risk of collection on these balances than the overall accounts receivable. The Company has decreased the allowance for doubtful accounts as a percentage of total accounts receivable to 28.6% at December 31, 2016 compared to 38.0% at December 31, 2015.

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):



	December 31, 2016							December 31, 2015
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	19,891	$	8,278	$	28,169		$	19,944	$	11,369	$	31,313
Commercial	97,744		19,848		117,592			94,477		20,213		114,690
Patient	3,955		6,825		10,780			5,014		6,025		11,039
Gross accounts receivable	$	121,590	$	34,951	156,541			$	119,435	$	37,607	157,042
Allowance for doubtful accounts					(44,730		)					(59,689		)
Net accounts receivable					$	111,811						$	97,353

Allowance for Contractual Discounts

The Company is reimbursed by payors for products and services the Company provides. Payments for medications and services covered by payors average less than billed charges. The Company monitors revenue and receivables from payors for each of our branches and records an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts reimbursed. Accordingly, the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from the payor. For the significant portion of the Company’s revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payor/product mix. Contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled. We do not believe these changes in estimates are material. The billing functions for the remaining portion of the Company’s revenue are largely computerized, which enables on-line adjudication (i.e., submitting charges to third-party payors electronically with simultaneous feedback of the amount the primary insurance plan expects to pay) at the time of sale to record net revenue, exposure to estimating contractual allowance adjustments is limited on this portion of the business.

Inventory

Inventory is recorded at the lower of cost or market. Cost is determined using specific item or the first-in, first-out method. Inventory consists principally of purchased prescription drugs and related supplies. Included in inventory is a reserve for inventory waste and obsolescence.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	years	-	5	years
Office equipment				5	years
Vehicles	4	years	-	5	years
Medical equipment	13	months	-	5	years
Furniture and fixtures				5	years

Leasehold improvements and assets leased under capital leases are depreciated using a straight-line basis over the related lease term or estimated useful life of the assets, whichever is less. The cost and related accumulated depreciation of assets sold or retired are removed from the accounts with the gain or loss, if applicable, recorded in the statement of operations. Maintenance and repair costs are expensed as incurred.

Costs relating to the development of software for internal purposes are charged to expense until technological feasibility is established in accordance with FASB ASC Topic 350, Intangibles – Goodwill and Other (“ASC 350”). Thereafter, the remaining software production costs up to the date placed into production are capitalized and included in Property and Equipment. Costs of customization and implementation of computer software purchased for internal use are likewise capitalized. Depreciation of the capitalized amounts commences on the date the asset is ready for its intended use and is calculated using the straight-line method over the estimated useful life of the software.

Goodwill

Goodwill is not subject to amortization but is instead tested for impairment annually and whenever events or circumstances exist that indicate that the carrying value of goodwill may no longer be recoverable in accordance with ASC 350. Management considers the Company’s business as a whole to be its reporting unit for purpose of testing for impairment since the Company no longer has multiple operating segments with the sale of the PBM Business. Management may choose to undertake a qualitative assessment in order to assess whether a quantitative analysis is required. In determining whether management will utilize the qualitative assessment in any one year, management will consider overall economic factors as well as the passage of time between the last quantitative assessment. In the event management determines that a quantitative assessment is required, this quantitative impairment testing is based on a two-step process. The first step compares the fair value of the reporting unit to its carrying amount including goodwill. If the first step quantitative analysis indicates that the fair value of the reporting unit is less than its carrying amount, the second step quantitative analysis must be performed to determine the implied fair value of reporting unit goodwill. The measurement of possible impairment is based on the comparison of the implied fair value of reporting unit goodwill to its carrying value.

Intangible Assets

The Company evaluates the useful lives of its intangible assets to determine if they are finite or indefinite-lived. Finite-lived intangible assets, primarily acquired customer relationships, trademarks and non-compete agreements, are amortized on a straight-line basis over their estimated useful lives.

Impairment of Long Lived Assets

The Company evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long lived assets, including intangible assets, may warrant revision or that the remaining balance of an asset may not be recoverable. The measurement of possible impairment is based on the ability to recover the balance of assets from expected future operating cash flows on an undiscounted basis. Impairment losses, if any, are determined based on the fair value of the asset, calculated as the present value of related cash flows using discount rates that reflect the inherent risk of the underlying business.

Amounts due to Plan Sponsors

Amounts due to Plan Sponsors primarily represent payments received from Plan Sponsors in excess of the contractually required reimbursement. These amounts are refunded to Plan Sponsors. These payables also include the sharing of manufacturers’ rebates with Plan Sponsors.

Revenue Recognition

The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company’s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements includes pharmacy agreements, where we dispense prescription medications through the Company’s pharmacy facilities.

FASB ASC Subtopic 605-25, Revenue Recognition: Multiple-Element Arrangements (“ASC 605-25”), addresses situations in which there are multiple deliverables under one revenue arrangement with a customer and provides guidance in determining whether multiple deliverables should be recognized separately or in combination. The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from ASC 605-25, the Company concluded that separate units of accounting exist in revenue arrangements with multiple deliverables. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service. The Company allocates revenue consideration based on the relative fair value as determined by the Company’s best estimate of selling price to separate the revenue where there are multiple deliverables under one revenue arrangement.

The Company also recognizes nursing revenue as the estimated net realizable amounts from patients and third party payors for the infusion services rendered and products provided. This revenue is recognized as the treatment plan is administered to the patient and is recorded at amounts estimated to be received under reimbursement or payment arrangements with payors.

Cost of Revenue

Cost of revenue includes the costs of prescription medications, shipping and other direct and indirect costs, claims processing operations, and nursing services, offset by volume and prompt pay discounts received from pharmaceutical manufacturers and distributors and total manufacturer rebates.

Rebates

Manufacturers’ rebates are generally volume-based incentives that are earned and recorded upon purchase of the inventory. Rebates are recorded as a reduction of both inventory and cost of goods sold.

Lease Accounting

The Company accounts for operating leasing transactions by recording rent expense on a straight-line basis over the expected term of the lease starting on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses, as adjustments to straight-line rent expense over the expected term of the lease.

Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets recorded under capital leases are depreciated in the same manner as owned property.

Income Taxes

In November 2015, the FASB issued ASU 2015-17 as part of its Simplification Initiative. The amendments eliminate the guidance in Topic 740, Income Taxes, that required an entity to separate deferred tax liabilities and assets between current and noncurrent amounts in a classified balance sheet. The Company elected to early adopt this guidance on a prospective basis during the annual reporting period ended on December 31, 2015. There is no financial statement impact as a result of the Company’s early adoption of this guidance.

As part of the process of preparing the Company’s Consolidated Financial Statements, management is required to estimate income taxes in each of the jurisdictions in which it operates. The Company accounts for income taxes under ASC Topic 740, Income Taxes (“ASC 740”). ASC 740 requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets.

The Company files income tax returns, including returns for its subsidiaries, as prescribed by Federal tax laws and the tax laws of the state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the Consolidated Financial Statements when the recognition threshold and measurement attributes of ASC 740 are met. Interest and penalties related to unrecognized tax benefits are recorded as income tax expense.

Financial Instruments

The Company’s financial instruments consist mainly of cash and cash equivalents, receivables, accounts payable, accrued interest and its Revolving Credit Facility (defined below). The carrying amounts of cash and cash equivalents, receivables, accounts payable, accrued interest and its Revolving Credit Facility approximate fair value due to their fully liquid or short-term nature.

Accounting for Stock-Based Compensation

The Company accounts for stock-based compensation expense under the provisions of ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). At December 31, 2016, the Company has one stock-based compensation plan pursuant to which incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights (“SARs”), restricted stock, performance shares and performance units may be granted to employees and non-employee directors. Option and stock awards are typically settled by issuing authorized but unissued shares of the Company.

The Company accounts for its stock-based awards to employees and non-employee directors using the fair value method. The fair value of each option award is based on several criteria including, but not limited to, the valuation model used and associated input factors including principally stock price volatility and, to a lesser extent, expected term, dividend rate, and risk-free interest rate. The input factors used in the valuation model are based on subjective future expectations combined with management judgment. The fair value of each stock award is determined based on the closing price of the underlying common stock on the date of grant. The fair value of the award is amortized to expense on a straight-line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, including time elapsed, market conditions and/or performance conditions. Because of these requirements, the weighted average period for which the expense is recognized varies. The Company expenses SAR awards based on vesting requirements. In addition, because they are settled with cash, the fair value of the SAR awards are revalued on a quarterly basis.

Recent Accounting Pronouncements

In August 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently assessing the impact of this new standard on its financial statements.

In March 2016, the FASB issued ASU 2016-09—Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). ASU 2016-09 modifies the accounting for share-based payment awards, including income tax consequences, classification of awards as equity or liabilities, and classification on the statement of cash flows. The effective date for ASU 2016-09 is for annual periods beginning after December 15, 2016, and interim periods within those fiscal years. The adoption of this standard is not expected to have a material impact on the Company’s business, financial position, results of operations or liquidity.

In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842): requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

In July 2015, the FASB issued an update 2015-11—Inventory (Topic 330): Simplifying the Measurement of Inventory effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The adoption of this standard did not have a material impact on the Company’s business, financial position, results of operations or liquidity.

In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU 2015-03 “Interest - Imputation of Interest (subtopic 835-20): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. Early adoption is permitted and will be applied on a retrospective basis. As of December 31, 2016 we had $3.6 million and $8.8 million of deferred financing costs that were reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt. As of December 31, 2015 we had $3.3 million and $12.6 million of deferred financing costs that were reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt.

In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company is assessing the impact of this new standard on its financial statements and has not yet selected a transition method.

LOSS PER SHARE

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Loss Per Share

LOSS PER SHARE

Loss Per Share

The Company presents basic and diluted loss per share (“LPS”) for its common stock, par value $.0001 per share (“Common Stock”). Basic LPS is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted LPS is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and Series A and Series C Convertible Preferred Stock. Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Convertible Preferred Stock are determined using the “if converted” method.

The Company's Series A and Series C Convertible Preferred Stock, par value $.0001 per share (together, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing LPS when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines LPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted LPS for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Year Ended December 31,
	2016			2015			2014
Numerator:
Loss from continuing operations, net of income taxes	$	(34,367	)	$	(303,428	)	$	(149,920	)
(Loss) income from discontinued operations, net of income taxes	(7,139		)	3,721			2,452
Net loss	(41,506		)	(299,707		)	(147,468		)
Accrued dividends on Preferred Stock	(8,392		)	(6,120		)	—
Deemed dividends on Preferred Stock	(692		)	(3,690		)	—
Loss attributable to common stockholders	$	(50,590	)	$	(309,517	)	$	(147,468	)

Denominator - Basic and Diluted:
Weighted average number of common shares outstanding	93,740			68,710			68,476
Loss Per Common Share:
Loss from continuing operations, basic and diluted	$	(0.46	)	$	(4.56	)	$	(2.19	)
(Loss) income from discontinued operations, basic and diluted	(0.08		)	0.05			0.04
Loss per common share, basic and diluted	$	(0.54	)	$	(4.51	)	$	(2.15	)

The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the years ended December 31, 2016, 2015 and 2014 excludes the effect of securities issued in connection with the PIPE Transaction and the Rights Offering (see Note 4 - Stockholders’ (Deficit) Equity), as well as stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.

STOCKHOLDERS' DEFICIT

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Attributable to Parent [Abstract]

Stockholders' Deficit

STOCKHOLDERS’ DEFICIT

Securities Purchase Agreement

On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00, (b) 1,800,000 Class A warrants (the “Class A Warrants”), and (c) 1,800,000 Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the Series A Preferred Stock is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

As disclosed in the Company’s definitive proxy materials relating to the Company’s 2015 annual meeting of stockholders held on May 11, 2015 (the “2015 Annual Meeting”), the Company sought stockholder approval to remove certain conversion and voting restrictions affecting the Series A Preferred Stock and exercise restrictions affecting the PIPE Warrants (the “Stockholder Approval”). Until Stockholder Approval was obtained, the terms of the Series A Preferred Stock and the PIPE Warrants contained caps on the conversion of the Series A Preferred Stock into Common Stock and on the exercise of the PIPE Warrants to purchase Common Stock (the “Conversion Caps”) and a cap on the voting power (the “Voting Cap” and, together with the Conversion Caps, the “Caps”) that prevented the issuance of Common Stock if a single holder would own or vote more than 19.99% of the Common Stock or have more than 19.99% of the voting power. As a result of obtaining Stockholder Approval on May 11, 2015, the Caps and other restrictions and conditions relating to the holders and their respective affiliates’ ability to vote and convert their shares of Series A Preferred Stock and exercise the PIPE Warrants ceased to apply.

The Purchase Agreement contains customary representations, warranties and covenants, including covenants relating to, among other things, information rights, the Company’s financial reporting, tax matters, listing compliance under the NASDAQ Global Market, Stockholder Approval, use of proceeds, and potential requirements under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended to make a notice filing with respect to the exercise of the PIPE Warrants.

The Company repaid approximately $45.3 million of the Revolving Credit Facility indebtedness and accrued interest, representing 77% of the PIPE Transaction’s net proceeds.

The PIPE Transaction was the subject of a putative securities class action lawsuit (see Note 11 - Commitments and Contingencies).

The proceeds from the Purchase Agreement were allocated among the instruments based on their relative fair values as follows (in thousands):



	Relative Fair Value Allocation
Financial instruments:	March 9, 2015
Series A Preferred Stock ¹	$	59,355
PIPE Warrants ²	3,145
Total Investment	$	62,500

¹ The fair value of the Series A Preferred Stock was determined using a binomial lattice model using the following assumptions: volatility of 55%, risk-free rate of 0.92%, and a dividend rate of 11.5%. The model also utilized various assumptions about the time to maturity and conditions under which conversion features would be exercised.

² The fair value of the PIPE Warrants was determined using the Black Scholes model using the following assumptions: volatility of 55%, risk-free rate of 0.92%, and stated exercise prices. The model also utilized various assumptions about the time to maturity and conditions under which exercise would occur.

Series A, Series B, and Series C Convertible Preferred Stock

In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued 625,000 shares of Series A Preferred Stock at $100.00 per share. In connection with the Rights Offering (as defined below), the Company issued an additional 10,822 shares of Series A Preferred Stock at $100.00 per share. The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock as previously disclosed in the Annual Report. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum.

On June 10, 2016, in order to allow the shares of Common Stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the “Series B Exchange Agreement”) pursuant to which the PIPE Investors agreed:

i) to exchange 614,177 shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which have the same terms as the Series A Preferred Stock previously described in the Company’s prior public filings, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of Common Stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and

ii) to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve 3,600,000 shares of our Common Stock for the exercise of the PIPE Warrants.

On June 14, 2016, the Company entered into another Exchange Agreement (the “Series C Exchange Agreement”) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of Series C Preferred Stock.

Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange 614,177 shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the 11.5% per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified “Consolidated EBITDA” as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve 3,600,000 shares of Common Stock for the exercise of the PIPE Warrants.

As a result of the exchanges discussed above, there are currently (a) 21,645 shares of Series A Preferred Stock outstanding, of which 10,823 shares are owned by the PIPE Investors, (b) no shares of Series B Preferred Stock outstanding, and (c) 614,177 shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.

As of December 31, 2016, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $2.6 million and 75.5 million, respectively.

The Preferred Stock may, at the option of the holder, be converted into Common Stock. The conversion rate in effect at any applicable time for conversion of each share of Preferred Stock into Common Stock will be the quotient obtained by dividing the Liquidation Preference then in effect by the conversion price then in effect, plus cash in lieu of fractional shares. The initial conversion price for the Preferred Stock is $5.17, but is subject to adjustment from time to time upon the occurrence of certain events, including in the event of a stock split, a reverse stock split, or a dividend of Junior Securities (defined below) to the Company’s common stockholders.

Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company (each, a Liquidation Event), after satisfaction of all liabilities and obligations to creditors of the Company and distribution of any assets of the Company to the holders of any stock or debt that is senior to the Preferred Stock, and before any distribution or payment shall be made to holders of any Junior Securities, each holder of Preferred Stock will be entitled to (i) convert their shares of Series A Preferred Stock into Common Stock and receive their pro rata share of consideration distributed to the holders of Common Stock, or (ii) receive, out of the assets of the Company or proceeds thereof (whether capital or surplus) legally available therefor, an amount per share of Series A and Series C Preferred Stock, as applicable, equal to the Liquidation Preference. The initial Series A Liquidation Preference was equal to $100.00 per share and the initial Series C Preferred Stock Liquidation Preference was equal to $115.48 per share, each of which may be adjusted from time to time by the accrual of non-cash dividends. However, if, at any applicable date of determination of the Liquidation Preference, (i) any cash dividend has been declared but is unpaid or (ii) the Company has given notice (or failed to give such notice) of its intention to pay a cash dividend but such cash dividend has not yet been declared by the Company’s board of directors (the “Board”), then such cash dividends shall be deemed, for purposes of calculating the applicable Liquidation Preference, to be Accrued Dividends. Accrued Dividends are paid upon the occurrence of a Liquidation Event and upon conversion or redemption of the Preferred Stock.

The Company may pay a noncumulative cash dividend on each share of the Series A and Series C Preferred Stock when, as and if declared by the Board at a rate of 8.5% per annum on the liquidation preference then in effect. Cash dividends, if declared, are payable quarterly in arrears on January 1, April 1, July 1 and October 1 of each year, commencing on the first calendar day of the first July or October following the date of original issuance of the Series A and Series C Preferred Stock. If declared, cash dividends will begin to accrue on the first day of the applicable quarterly dividend period. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A and Series C Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum. If the Company pays a dividend or makes a distribution on the outstanding Common Stock (other than in Junior Securities, as defined below), the Company must, at the same time, pay each holder of the Series A and Series C Preferred Stock a dividend equal to the dividend the holder would have received if all of the holder’s shares of Series A and Series C Preferred Stock were converted into Common Stock immediately prior to the record date for the dividend payment (“Participating Dividend”). The Company would not be required to pay the Participating Dividend if the Company dividend or distribution was in Common Stock, a security ranking equal to or junior to Common Stock, or a security convertible into Common Stock or a security ranking equal to or junior to Common Stock (“Junior Securities”). Instead, where the Company makes a dividend or distribution of a Junior Security, the holder of Series A and Series C Preferred Stock is entitled to anti-dilution protection in the form of an adjustment to the conversion price of the Series A and Series C Preferred Stock. Unless and until the Company obtains the required consent and/or amendment from the Company’s lenders under the Company’s Senior Credit Facilities (as defined below), the Company will not be permitted to pay cash dividends.

From and after the tenth anniversary of the original issuance of the Series A and Series C Preferred Stock, each holder of shares of Series A and Series C Preferred Stock will have the right to request that the Company redeem, in full, out of funds legally available, by irrevocable written notice to the Company, all of such holder’s shares of Series A or Series C Preferred Stock at a redemption price per share equal to the Liquidation Preference then in effect per share of Series A or Series C Preferred Stock, as applicable. From and after the tenth anniversary of the original issuance of the Series A and Series C Preferred Stock, the Company may redeem the outstanding Series A and Series C Preferred Stock, in whole or in part, at a price per share equal to the Liquidation Preference then in effect.

The Series A and Series C Preferred Stock will, with respect to dividend rights and rights upon liquidation, winding up or dissolution, rank senior to the Company’s Common Stock and each other class or series of shares that the Company may issue in the future that do not expressly provide that such class or series ranks equally with, or senior to, the Series A and Series C Preferred Stock, with respect to dividend rights and/or rights upon liquidation, winding up or dissolution. The Series A and Series C Preferred Stock will also rank junior to the Company’s existing and future indebtedness. Holders of shares of Series A and Series C Preferred Stock will be entitled to vote with the holders of shares of Common Stock (and any other class or series similarly entitled to vote with the holders of Common Stock) and not as a separate class, at any annual or special meeting of stockholders of the Company, and may act by written consent in the same manner as the holders of Common Stock, on an as-converted basis. So long as shares of the Series A or Series C Preferred Stock represent at least five percent (5%) of the outstanding voting stock of the Company, a majority of the voting power of the Series A Preferred Stock or Series C Preferred Stock, as applicable, shall have the right to designate one (1) member to the Company’s Board who shall be appointed to a minimum of two (2) committees of the Board.

Carrying Value of Series A Preferred Stock

As of December 31, 2016, the following values were accreted as described above and recorded as a reduction of additional paid in capital in Stockholders’ Equity and a deemed dividend on the Statement of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to December 31, 2016. The following table sets forth the activity recorded during the year ended December 31, 2016 related to the Series A Preferred Stock (in thousands) issued for both the PIPE Transaction and the Rights Offering:



Series A Preferred Stock carrying value at December 31, 2015	$	62,918
Exchange of Series A for Series C	(60,776		)
Discount related to beneficial conversion feature	40
Dividends recorded through December 31, 2016 ¹	280
Series A Preferred Stock carrying value at December 31, 2016	$	2,462

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Carrying Value of Series C Preferred Stock



Series C Preferred Stock carrying value at December 31, 2015	$	—
Exchange of shares - Series A to Series C	60,776
Accretion of discount related to issuance costs	652
Dividends recorded through December 31, 2016 ¹	8,112
Series C Preferred Stock carrying value at December 31, 2016	$	69,540

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

PIPE Warrants

In connection with the PIPE Transaction, the Company issued 1,800,000 Class A Warrants and 1,800,000 Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of Class A Warrants and Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

The PIPE Warrants are exercisable for a ten year term and may only be exercised for cash. The number of shares of Common Stock that may be acquired upon exercise of the PIPE Warrants is subject to anti-dilution adjustments for stock splits, subdivisions, reclassifications or combinations, or the issuance of Common Stock for a consideration per share less than 85% of the market price per share immediately prior to such issuance. Upon the occurrence of certain business combinations, the PIPE Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.

The PIPE Warrants became exercisable on May 11, 2015, the date Stockholder Approval was obtained at the 2015 Annual Meeting.

The following sets forth the carrying value of the PIPE Warrants which is classified as equity on the Consolidated Balance Sheet (in thousands):



	Carrying Value
PIPE Warrants	March 9, 2015
Fair value allocated to PIPE Warrants	$	3,145
Discount related to issuance costs	(203		)
Carrying value of PIPE Warrants	$	2,942

The Company entered into a registration rights agreement, as amended (the “Registration Rights Agreement”), with the PIPE Investors that, among other things and subject to certain exceptions, requires the Company, upon the request of the PIPE Investors, to register the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A and Series C Preferred Shares or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, the costs incurred in connection with such registrations will be borne by the Company. As provided under the Registration Rights Agreement, the Company on April 1, 2016 filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), to register, among other things, the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A and Series C Preferred Shares.

Rights Offering

On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering expired on July 27, 2015 and was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.

With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.

Shelf Registration Statement

The Company filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the “2016 Shelf”). Under the 2016 Shelf at the time of effectiveness, the Company had the ability to raise up to $200.0 million, in one or more transactions, by selling Common Stock, preferred stock, debt securities, warrants, units and rights.

2016 Equity Offering

On June 22, 2016, the Company completed an underwritten public offering of 45,200,000 shares of Common Stock, including 5,200,000 shares of Common Stock issued upon the underwriters’ full exercise of the over-allotment option, at a public offering price of $2.00 per share, less underwriting discounts and commissions and offering expenses payable by us (the “2016 Equity Offering”). The Company received net proceeds of approximately $83.3 million from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering expenses.

A portion of the net proceeds from the 2016 Equity Offering was used fund the Cash Consideration (as defined below) and pay fees and expenses in connection with the closing of the Home Solutions Transaction (see below).

Home Solutions Transaction

On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of HS Infusion Holdings, Inc. (“Home Solutions”) and its subsidiaries (the “Home Solutions Transaction”) pursuant to an Asset Purchase Agreement dated June 11, 2016 (as amended, the “Home Solutions Agreement”), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the “First Amendment”), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. On September 2, 2016, the same parties entered into a second amendment to the Home Solutions Agreement (the “Second Amendment”), which amended the Home Solutions Agreement to eliminate the condition to closing that the Company receive stockholder approval to increase its authorized share capital (the “Charter Amendment”) and facilitated the timely consummation of the Home Solutions Transaction. The Second Amendment instead provided that the Company will hold a stockholder meeting after the closing of the Home Solutions Transaction to seek stockholder approval of the Charter Amendment, and if the approval is not obtained at the first special meeting, the Company will submit the proposal on a twice per year basis beginning in 2017, at either the annual meeting or a special meeting of stockholders.

The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) $67.5 million in cash (the “Cash Consideration”); plus (ii) (a) 3,750,000 shares of Company common stock (the “Transaction Closing Equity Consideration”) and (b) the right to receive contingent equity securities of the Company, in the form of restricted shares of Company common stock (the “RSUs”), issuable in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the “Contingent Shares”). The number of shares of Company common stock in Tranche A will be approximately 3.1 million. The number of shares of Company common stock in Tranche B will be approximately 4.0 million. Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration rights that required us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder’s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act. The Company filed the registration statement on October 7, 2016 and it was declared effective on October 27, 2016.

The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $4.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $4.00 per share. The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $5.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $5.00 per share. The Home Solutions Agreement provides for a cash settlement option related to the RSUs, effective June 15, 2021, if, and only if, authorized shares are unavailable when the vesting conditions of Tranche A and Tranche B are met. At the date of acquisition, the Company did not have sufficient authorized shares available to satisfy the issuance of Tranche A and Tranche B RSUs and, accordingly, recognized a liability for the fair value of the contingent consideration. As of November 30, 2016, upon approval of the Charter Amendment, the Company has sufficient authorized shares available should the vesting conditions be met and the RSUs become issuable. The liability was reclassified to equity and a gain on the change in the fair value of the RSUs was recognized as of November 30, 2016.

The Cash Consideration and the Transaction Closing Equity Consideration were paid at closing and were funded by cash on-hand and borrowings from our Revolving Credit Facility.

Authorized Shares

On November 30, 2016, the stockholders of the Company approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from 125 million shares to 250 million shares (the “Charter Amendment”).

Treasury Stock

During the years ended December 31, 2016 and 2015, 13,570 and 16,952 shares, respectively, were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards. The Company does not hold any shares of treasury stock at December 31, 2016 as the balance was utilized to issue shares, reflected as consideration, in the Home Solutions acquisition.

Common Stock Purchase Warrants Issued in 2010

In connection with the acquisition of Critical Homecare Solutions Holdings, Inc. (“CHS”) in March 2010, the Company issued 3.4 million warrants exercisable for the Company’s Common Stock (the “2010 Warrants”). The 2010 Warrants had a five year term with an exercise price of $10.00 per share. They were exercisable at any time prior to the expiration date of March 25, 2015. The Company determined that the 2010 Warrants meet the conditions for equity classification in accordance with GAAP. Therefore, the 2010 Warrants were classified as equity and included in additional paid-in capital.

No 2010 Warrants were exercised prior to their March 25, 2015 expiration.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

ACQUISITIONS

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

Home Solutions

On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of Home Solutions and its subsidiaries pursuant to the Home Solutions Agreement. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions.

The aggregate consideration paid by the Company in the Transaction was equal to (i) $67.5 million in cash (the “Cash Consideration); plus (ii) (a) 3,750,000 shares of Company common stock (the “Transaction Closing Equity Consideration”) and (b) the right to receive contingent equity securities of the Company, in the form of restricted shares of Company common stock (the “RSUs”), issuable in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the “Contingent Shares”). The number of shares of Company common stock in Tranche A will be approximately 3.1 million. The number of shares of Company common stock in Tranche B will be approximately 4.0 million. Upon close of the Transaction the RSUs had no intrinsic value, but were reported as a liability in our consolidated financial statements at their estimated fair value at the date of issuance. Upon approval of the Charter Amendment on November 30, 2016, the date at which sufficient shares were available should the RSUs vest and become issuable, the liability was remeasured to its current fair value and reclassified to equity.

The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):



Cash	$	67,516
Equity issued at closing	9,938
Capital lease obligation assumed	301
Fair value of contingent consideration	15,400
Total consideration	$	93,155

The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions as of September 9, 2016 (in thousands):



Accounts receivable	$	11,956
Inventories	3,199
Prepaids and other assets	852
Total current assets	$	16,007
Property and equipment	4,651
Goodwill	57,218
Managed care contracts	24,700
Licenses	5,400
Trade name	1,800
Non-compete agreements	200
Other long-term assets	891
Total assets	$	110,867
Accounts payable	14,576
Accrued liabilities	3,136
Total liabilities	$	17,712
Net assets acquired	$	93,155

The excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of the goodwill represents the value the Company expects to be created by combining the operations of the companies, including the ability to cross-sell its services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.

In accordance with ASC Topic 805 Business Combinations, the allocation of the purchase price is subject to adjustment during the measurement period after the closing date (September 9, 2016) when additional information on assets and liability valuations becomes available. The Company has not finalized its valuation of certain assets and liabilities recorded pursuant to the acquisition including intangible assets and contingent consideration. Thus, the provisional measurements recorded are subject to change. Any changes will be recorded as adjustments to the fair value of the assets and liabilities with residual amounts allocated to goodwill.

Under the Home Solutions Agreement, the Company did not purchase, among other things, any accounts receivable associated with governmental payors. However, the Home Solutions Agreement stipulates that collections of government receivables, as of the first anniversary of the closing date, in an amount less than the amount estimated as government receivables in the Closing Certificate, must be paid to the seller. The Company believes the government receivables will be collected and, as a result, has not recorded a liability for the guarantee.

The Company has consolidated the results of Home Solutions for the period of control within its Consolidated Statements of Operations for the year ended December 31, 2016. Inclusion of Home Solutions’ operating results within the Company’s Consolidated Statements of Operations contributed $26.8 million in revenue, $9.2 million in gross profit, and $3.2 million in net income for the year ended December 31, 2016.

Pro Forma Impact of Acquisition

The following table sets forth the unaudited pro forma combined results of operations as if the acquisition of Home Solutions had occurred at the beginning of the periods presented. Adjustments made to the financial information give effect to pro forma events that are (1) directly attributable to the acquisition, (2) factually supportable, and (3) with respect to the statement of operations, expected to have a continuing impact on the combined results. The pro forma financial information does not reflect revenue opportunities and cost savings that the Company expects to realize as a result of the acquisition of Home Solutions. The pro forma financial information includes acquisition related charges incurred prior to December 31, 2016, and does not reflect estimates of charges related to the integration activity or exit costs that may be incurred by BioScrip in connection with the acquisition in future periods.



	Years Ended December 31,
Pro forma impact of acquisition (in millions, except for per share amounts):	2016			2015			2014
Revenues	$	1,019		$	1,091		$	1,028
Gross profit	$	288		$	289		$	277
Gross profit percentage	28.3		%	26.5		%	26.9		%
Loss from continuing operations, net of income taxes	$	(44	)	$	(322	)	$	(178	)
Basic loss per share from continuing operations	$	(0.47	)	$	(4.68	)	$	(2.60	)
Diluted loss per share from continuing operations	$	(0.47	)	$	(4.68	)	$	(2.60	)

The pro forma results for the year ended December 31, 2016 includes $10.1 million of acquisition related expenses.

Acquisition and Integration Expense

Acquisition and integration expenses in restructuring, acquisition, integration, and other expenses, net in the accompanying Consolidated Statements of Operations for the years ended December 31, 2016, 2015 and 2014 include the following costs related to the Home Solutions, CarePoint Business, and the HomeChoice acquisitions (in thousands):



	Year Ended December 31,
	2016		2015		2014
Legal and professional fees	$	3,059	$	1,033	$	6,931
Financial advisory fees	5,087		—		—
Employee costs including redundant salaries and benefits and severance	—		—		2,016
Facilities consolidation and discontinuation	1,323		488		1,401
Bad debt expense and contractual adjustments related to acquired accounts receivable	—		—		5,430
Legal settlement	—		—		334
Other	653		219		1,812
Total	$	10,122	$	1,740	$	17,924

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

DISCONTINUED OPERATIONS

12 Months Ended

Dec. 31, 2016

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

Sale of PBM Services

On August 27, 2015, the Company completed the sale of substantially all of the Company’s PBM Services segment (as defined above, the “PBM Business”) pursuant to an Asset Purchase Agreement dated as of August 9, 2015 (the “Asset Purchase Agreement”), by and among the Company, BioScrip PBM Services, LLC and ProCare Pharmacy Benefit Manager Inc. (the “PBM Buyer”). Under the Asset Purchase Agreement, the PBM Buyer agreed to acquire substantially all of the assets used solely in connection with the PBM Business and to assume certain PBM Business liabilities (the “PBM Sale”). On the Closing Date, pursuant to the terms of the Asset Purchase Agreement, the Company received total cash consideration of approximately $24.6 million, including an adjustment for estimated Closing Date net working capital. On October 20, 2015, the Company finalized working capital adjustment negotiations in relation to the PBM Sale whereby the Company agreed to repay approximately $1.0 million to the PBM Buyer. The Company used the net proceeds from the PBM Sale to pay down a portion of the Company’s outstanding debt.

The sale of the PBM Business was consistent with the Company’s continuing strategic evaluation of its non-core businesses and its decision to continue to focus growth initiatives and capital in the Infusion Services business. As a result, the Company has reclassified its operations to discontinued operations for all prior periods in the accompanying Consolidated Financial Statements.

As of the August 27, 2015 closing date of the sale of the PBM Business, the carrying value of the net assets of the PBM Business was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	7,163
Total current assets	7,163
Property and equipment, net	175
Goodwill	12,744
Total assets	20,082
Amounts due to plan sponsors	6,950
Total liabilities	6,950
Net assets	$	13,132

The operating results included in discontinued operations of the PBM Business for the years ended December 31, 2016, 2015 and 2014 are summarized as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Revenue	$	—		$	44,375		$	61,401
Gross profit	$	—		$	9,763		$	17,635
Other operating expenses	1,015			5,444			10,878
Bad debt expense	—			(45		)	27
(Loss) income from operations	(1,015		)	4,364			6,730
Gain on sale before income taxes	—			(11,424		)	—
Financial advisory fee and legal expenses	614			1,731			—
Other income and expenses, net	(326		)	1,898			(6		)
(Loss) income before income taxes	(1,303		)	12,159			6,736
Income tax expense	—			206			198
(Loss) income from discontinued operations, net of income taxes	$	(1,303	)	$	11,953		$	6,538

Sale of Home Health Business

On March 31, 2014, the Company completed the sale of substantially all of the Company’s Home Health Services segment (the “Home Health Business”) pursuant to the Stock Purchase Agreement dated as of February 1, 2014 (the “Stock Purchase Agreement”). Pursuant to the terms of the Stock Purchase Agreement, as amended, the Company received total consideration of approximately $59.5 million paid in cash (the “Purchase Price”) at closing. The Company used a portion of the net proceeds from the sale to pay down a portion of the Company’s outstanding debt. Subsequently, the Purchase Price was adjusted for net working capital of the divested Home Health Business companies (the “Subject Companies”) as of the closing date that resulted in an additional payment to the Company of approximately $1.1 million. As a result of this adjustment, the final Purchase Price received by the Company was approximately $60.6 million. The Company has classified the net proceeds received from this sale in cash provided by investing activities from discontinued operations in the accompanying consolidated statements of cash flows.

The sale of the Home Health Business was consistent with the Company’s continuing strategic evaluation of its non-core businesses and its decision to continue to focus growth initiatives and capital in the Infusion Services business. As a result, the Company decided in the second quarter of 2014 to cease the material portion of its Home Health operations at the one location excluded from the Stock Purchase Agreement, as amended, and reclassified its operations to discontinued operations for all prior periods in the accompanying Consolidated Financial Statements.

As of the March 31, 2014 closing date of the sale of the Home Health Business, the carrying value of the net assets of the Subject Companies was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	12,597
Prepaid expenses and other current assets	242
Total current assets	12,839
Property and equipment, net	402
Goodwill	33,784
Intangible assets	15,400
Other non-current assets	28
Total assets	62,453
Accounts payable	673
Amounts due to plan sponsors	229
Accrued expenses and other current liabilities	3,008
Total liabilities	3,910
Net assets	$	58,543

The pre-tax gain on sale of the Home Health Business is approximately $2.1 million based on the March 31, 2014 net asset balances above and before financial advisory fees, legal expenses and other one-time transactions costs and including the net working capital adjustment. The net assets of the Subject Companies have been reclassified to discontinued operations for all prior periods in the accompanying Consolidated Financial Statements.

The operating results included in discontinued operations of the Home Health Business for the years ended December 31, 2016, 2015 and 2014 are summarized as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Revenue	$	—		$	—		$	18,551
Gross profit	$	—		$	—		$	6,918
Other operating expenses	—			417			8,219
Bad debt expense	—			—			902
Loss from operations	—			(417		)	(2,203		)
Gain on sale before income taxes	—			—			(2,067		)
Financial advisor fee and legal expenses	(44		)	—			2,875
Impairment of assets	—			—			452
Other costs and expenses	(118		)	861			47
Income (loss) before income taxes	162			(1,278		)	(3,510		)
Income tax expense (benefit)	—			—			(4,257		)
Income (loss) from discontinued operations, net of income taxes	$	162		$	(1,278	)	$	747

Pharmacy Services Asset Sale

On February 1, 2012, the Company entered into a Community Pharmacy and Mail Business Purchase Agreement by and among Walgreen Co. and certain subsidiaries and the Company and certain subsidiaries (collectively, the “Sellers”) with respect to the sale of certain assets, rights and properties relating to the Sellers’ traditional and specialty pharmacy mail operations and community retail pharmacy stores.

The operating results included in discontinued operations of the divested traditional and specialty pharmacy mail operations and community pharmacies for the years ended December 31, 2016, 2015 and 2014 are summarized as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Revenue	$	—		$	—		$	—
Gross profit	$	—		$	—		$	(439	)
Other operating expenses	185			4,485			3,995
Legal fees and settlement expense	2			1,312			—
Other (income) expense, including gain on sale	17			1,157			399
Loss from discontinued operations, net of income taxes	$	(204	)	$	(6,954	)	$	(4,833	)

On December 28, 2016, in response to a lawsuit filed by the Sellers alleging that the Company and certain of its subsidiaries breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement, an arbitrator awarded Walgreens $5.8 million in damages constituting approximately 3% of the total sales Walgreens claimed were made in violation of the agreement. The Company filed a motion to vacate the arbitration award but cannot provide assurance that its challenge will be successful. As a result, $5.8 million was accrued for the settlement in discontinued operations.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill, and the changes in the carrying amount of goodwill for the years ended December 31, 2016 and 2015, are as follows (in thousands):



	Infusion Services
Balance at December 31, 2014	$	573,323
Impairment	(251,850		)
Disposition of PBM Services	(12,744		)
Balance at December 31, 2015	308,729
Acquisition of Home Solutions	57,218
Balance at December 31, 2016	$	365,947

In accordance with ASC 350, Intangibles--Goodwill and Other, the Company evaluates goodwill for impairment on an annual basis and whenever events or circumstances exist that indicates that the carrying value of goodwill may no longer be recoverable. Management may choose to undertake a qualitative assessment (step zero approach) in order to assess whether a quantitative analysis is required. In determining whether management will utilize the qualitative assessment in any one year, management will consider overall economic factors as well as the passage of time between the last quantitative assessment. In the event management determines that a quantitative assessment is required, this quantitative impairment testing is based on a two-step process. The first step quantitative analysis compares the fair value of a reporting unit with its carrying amount, including goodwill. If the first step indicates that the fair value of the reporting unit is less than its carrying amount, the second step quantitative analysis must be performed to determine the implied fair value of reporting unit goodwill. The measurement of possible impairment is based upon the comparison of the implied fair value of reporting unit to its carrying value.

In the first quarter of 2015, we performed our annual goodwill impairment test and estimated the fair value of each of our reporting units as of the end of our most recent fiscal year. We concluded that the estimated fair value determined under our testing approach for each of our reporting units, as of December 31, 2014, was reasonable. In each case, the estimated fair value exceeded the respective carrying value. We concluded that the goodwill assigned to each reporting unit, as of March 31, 2015, was not impaired and that neither reporting unit was at risk of failing Step 1 of the goodwill impairment test as prescribed under the ASC.

In the second quarter of 2015, business conditions had not significantly improved and our stock price declined. As a result, we concluded that it was appropriate for us to perform a quantitative Step 1 interim goodwill impairment test as of June 30, 2015. Taking into consideration our updated business outlook for the remainder of fiscal 2015, we updated our future cash flow assumptions for our Infusion Services reporting unit and calculated updated estimates of fair value using the three method valuation approach. After updating our assumptions and projections, we then calculated an estimate of fair value for the reporting unit, consistent with our annual impairment test on December 31, 2014. As of June 30, 2015, we determined that our Infusion Services reporting unit had an indication of impairment and we proceeded to a Step 2 analysis to determine the amount of the goodwill impairment.

Our fair value for each reporting unit is determined based on a guideline public company analysis or market approach which utilizes current earnings multiples of comparable publicly-traded companies, a guideline transaction analysis which utilizes select actual comparable industry transactions and a discounted cash flow analysis which uses significant unobservable inputs, or level 3 inputs, as defined by the fair value hierarchy. We equally weighted the valuation of our reporting units based on the three methods. We believe that this weighting is appropriate.

The Step 2 analysis included determining the fair value of inventory, intangible assets, debt, and other current assets and liabilities, as well as fair values of equipment and fixtures. Key assumptions used in the impairment test included: growth rates ranging from 3.0% to 5.0%, EBITDA margins of 6% to 8%, and discount rates applied ranging from 9.0% to 11.0%.

The accounting principles regarding goodwill acknowledge that the observed market prices of individual trades of a company's stock (and thus its computed market capitalization) may not be representative of the fair value of the company as a whole. Additional value may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity. Consequently, measuring the fair value of a collection of assets and liabilities that operate together in a controlled entity is different from measuring the fair value of that entity's individual common stock. In most industries, including ours, an acquiring entity typically is willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. We have taken into consideration the current trends in our market capitalization and the current book value of our equity in relation to fair values arrived at in our interim fiscal 2015 goodwill impairment analysis, including the implied control premium, and have deemed the result to be reasonable.

Our goodwill impairment analysis is sensitive to changes in key assumptions used in our analysis, such as expected future cash flows, the degree of volatility in equity and debt markets, and our stock price. If the assumptions used in our analysis are not realized, it is possible that an impairment charge may need to be recorded in the future. We cannot accurately predict the amount and timing of any impairment of goodwill or other intangible assets. Further, as we continue to work towards a turnaround of our business, we will need to continue to evaluate the carrying value of our goodwill. Any additional impairment charges that we may take in the future could be material to our results of operations and financial condition.

During the third quarter of 2015, the Company finalized its second quarter impairment assessment and as a result recorded a total impairment charge of $251.9 million year to date, all of which related to our Infusion Services reporting unit. The Company evaluated goodwill for possible impairment during the quarter ending December 31, 2015 utilizing the Step 0 approach which was utilized in light of the recent detailed analysis performed in the second quarter and completed in the third quarter. In light of this assessment the Company determined that a two-steps approach analysis was not required and likewise no further impairment charge was needed.

The Company evaluated goodwill for possible impairment as of the year ending December 31, 2016 for the Infusion Services reporting unit utilizing the Step 1 approach, the results of which did not indicate impairment. The Company has concluded that the goodwill assigned to the Infusion Services business was not impaired, rendering further analysis unnecessary.

Intangible assets consisted of the following as of December 31, 2016 and 2015 (in thousands):



	December 31, 2016							December 31, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite Lived Assets
Infusion customer relationships	$	25,650	$	(23,768	)	$	1,882	$	25,650	$	(20,789	)	$	4,861
Managed care contracts	24,700		(1,898		)	22,802		—		—			—
Licenses	5,400		(906		)	4,494		—		—			—
Trade name	1,800		(281		)	1,519		—		—			—
Non-compete agreements	1,700		(1,354		)	346		1,500		(1,233		)	267
	$	59,250	$	(28,207	)	$	31,043	$	27,150	$	(22,022	)	$	5,128

Finite lived intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:



	Estimated Useful Life
Infusion customer relationships	5	months		-	4	years
Managed care contracts					4	years
Licenses					2	years
Trade name					2	years
Non-compete agreements		1	year	-	5	years

Total amortization expense of intangible assets was $6.2 million, $5.1 million, and $6.6 million for the years ended December 31, 2016, 2015, and 2014, respectively. Amortization expense is expected to be the following (in thousands):



Year ending December 31,	Estimated Amortization
2017	$	11,925
2018	8,821
2019	6,121
2020	4,176
2021	—
Thereafter	—
Total estimated amortization expense	$	31,043

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSE, NET

12 Months Ended

Dec. 31, 2016

Restructuring and Related Activities [Abstract]

Restructuring, Acquisition, Integration, and Other Expense, Net

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSE, NET

Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.

Restructuring, acquisition, integration, and other expenses, net in the Consolidated Statements of Operations for the years ended December 31, 2016, 2015, and 2014 consisted of the following (in thousands):



	Year Ended December 31,
	2016			2015		2014
Restructuring expense	$	10,334		$	22,635	$	19,646
Acquisition and integration expenses	10,122			1,740		17,924
Change in fair value of contingent consideration	(4,597		)	30		(7,364		)
Total restructuring, acquisition, integration, and other expenses, net	15,859			24,405		30,206

On August 10, 2015, the Company announced a plan to implement a new operations financial improvement plan (the “Financial Improvement Plan”) as part of an initiative to accelerate long-term growth, reduce costs and increase operating efficiencies. In connection with the Financial Improvement Plan, the Company consolidated most corporate functions from our Eden Prairie, Minnesota corporate office and our Elmsford, New York executive office into our new executive and corporate office located in Denver, Colorado. The Financial Improvement Plan was substantially completed by the end of 2015.

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment consists of the following (in thousands):



	December 31,
	2016			2015
Computer and office equipment	$	29,556		$	22,561
Software capitalized for internal use	16,481			15,600
Vehicles	2,552			1,938
Medical equipment	31,509			28,423
Work in progress	5,746			6,624
Furniture and fixtures	5,318			4,543
Leasehold improvements	16,464			14,285
Property and equipment, gross	107,626			93,974
Less: Accumulated depreciation	(75,091		)	(62,035		)
Property and equipment, net	$	32,535		$	31,939

Work in progress at December 31, 2016 and 2015 includes $5.8 million and $1.8 million, respectively, of internally developed software costs to be capitalized upon completion.

Depreciation expense, including expense related to assets under capital lease, for the years ended December 31, 2016, 2015 and 2014 was $15.4 million, $17.6 million, and $16.4 million, respectively. Depreciation expense for the years ended December 31, 2016, 2015 and 2014 includes $2.2 million, $2.5 million, and $2.4 million, respectively, related to costs related to software capitalized for internal use.

Impairment

The Company, which assesses the impairment of its assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable, has determined that no such events or changes have occurred and therefore, no impairment charge in relation to property, plant and equipment was incurred during the year ended December 31, 2016.

DEBT

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Debt

DEBT

As of December 31, 2016 and 2015, the Company’s debt consisted of the following (in thousands):



	December 31,
	2016			2015
Revolving Credit Facility	$	55,300		$	15,000
Term Loan Facilities	210,207			222,757
2021 Notes, net of unamortized discount	196,670			196,038
Capital leases	2,209			189
Less: Deferred financing costs	(12,452		)	(15,863		)
Total Debt	451,934			418,121
Less: Current portion	(18,521		)	(24,380		)
Long-term debt, net of current portion	$	433,413		$	393,741

Senior Credit Facilities

On July 31, 2013, the Company entered into (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank (“Sun Trust”), Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc.

The Senior Credit Facilities contain customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness, events constituting a change of control and any other development that results in, or would reasonably be expected to result in, a material adverse effect to the debtor’s ability to perform its obligation under the facility. The occurrence of certain events of default may increase the applicable rate of interest by 2% and could result in the acceleration of the Company’s obligations under the Senior Credit Facilities to pay the full amount of the obligations.

The proceeds of the Term Loan B Facility were used to refinance certain existing indebtedness of the Company, including the payment of the purchase price for the 10.25% senior unsecured notes (the “2015 Notes”) tendered and accepted for purchase in the Offer (defined below) and the payment of the redemption price for the 2015 Notes that remained outstanding after completion of the Offer. The Delayed Draw Term Loan Facility and the Revolving Credit Facility were used to fund a portion of the CarePoint Business acquisition and may be used for other general corporate purposes of the Company, including acquisitions, investments, capital expenditures and working capital needs.

On December 23, 2013, the Company entered into the First Amendment to the Senior Credit Facilities pursuant to which the Company obtained the required consent of the lenders to enter into the Settlement Agreements (see Note 11 - Commitments and Contingencies) and to begin making payments, in accordance with the payment terms, on the settlement amount of $15.0 million. In exchange for this consent, the Company paid the lenders a fee of $0.5 million and included this amount in loss from discontinued operations in the Consolidated Statements of Operations.

On January 31, 2014, the Company entered into the Second Amendment to the Senior Credit Facilities, which, among other things (i) provides additional flexibility with respect to compliance with the maximum net leverage ratio for the fiscal quarters ending December 31, 2013 through and including December 31, 2014, (ii) provides additional flexibility under the indebtedness covenants to permit the Company to obtain up to $150.0 million of second-lien debt and issue up to $250.0 million of unsecured bonds, provided that 100% of the net proceeds are applied first to the Revolving Credit Facility, with no corresponding permanent commitment reduction, and then on a pro rata basis to the Term Loan B Facility and the Delayed Draw Term Loan Facility (collectively, the “Term Loan Facilities”), (iii) provides the requisite flexibility to sell non-core assets, subject to the satisfaction of certain conditions, and (iv) increased the applicable interest rates for each of the Term Loan Facilities to the Eurodollar rate plus 6.00% or the base rate plus 5.00%, until the occurrence of certain pricing decrease triggering events, as defined in the amendment. Upon the occurrence of a pricing decrease triggering event, the interest rates for the Senior Credit Facilities may revert to the Eurodollar rate plus 5.25% or the base rate plus 4.25%.

On March 1, 2015, the Company entered into the Third Amendment to the Senior Credit Facilities (the “Third Amendment”), which establishes an alternate leverage test for the fiscal quarters ending March 31, 2015 through and including March 31, 2016. The maximum net leverage ratio for these quarters is consistent with that in effect for the prior four fiscal quarters. The Third Amendment eliminated the need to meet progressively lower leverage ratio requirements at each quarter end date for the next four quarters. The Third Amendment also provides for certain additional financial reporting.

On August 6, 2015, the Company entered into a Fourth Amendment to its Senior Credit Facilities (the “Fourth Amendment”). The Fourth Amendment, among other things, provides additional relief with respect to measuring compliance with the maximum first lien net leverage ratio for the fiscal quarters ending September 30, 2015 through and including March 31, 2017 and modifies and extends an alternate leverage test for the fiscal quarters ending September 30, 2015 through and including March 31, 2017. The levels for the maximum first lien net leverage ratio for certain of these quarters were increased by the Fourth Amendment. The availability of the alternative first lien net leverage ratio is subject to a number of conditions, including a minimum liquidity requirement and a maximum utilization test that requires the Revolving Credit Facility balance to remain under $60.0 million for the alternative first lien net leverage ratio to apply.

On October 9, 2015, the Company entered into the Fifth Amendment to the Senior Credit facilities (the “Fifth Amendment”), The Fifth Amendment directly modifies the definition of a “Continuing Director” in full as, “with respect to any period, any individuals (A) who were members of the board of directors or other equivalent governing body of the Borrower on the first day of such period, (B) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (A) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body, or (C) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (A) and (B) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body.” This amended definition also indirectly modifies the definition of a “Change in Control.”

On January 6, 2017, the Company entered into a sixth amendment (the “Sixth Amendment”) to its credit agreement dated as of July 31, 2013, with SunTrust Bank, Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., as amended on December 23, 2013, January 31, 2014, March 1, 2015, August 6, 2015 and October 9, 2015. Also, on January 6, 2017, the Company entered into a new credit agreement (the “Priming Credit Agreement”) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provides an aggregate borrowing commitment of $25,000,000, which was fully drawn at closing. (See Note 17 - Subsequent Events).

As discussed below, the net proceeds of approximately $194.5 million from the issuance on February 11, 2014 of 8.875% senior notes due 2021 (the “2021 Notes”) were used to repay $59.3 million of the Revolving Credit Facility and $135.2 million of the Term Loan Facilities. In addition, approximately $54.2 million of the net proceeds from the sale of the Home Health Business (see Note 6 - Discontinued Operations) were used to repay $17.2 million of the Revolving Credit Facility and $37.0 million of the Term Loan Facilities. The Senior Credit Facilities are secured by substantially all of the Company’s and its subsidiaries’ assets.

The partial repayments of the Senior Credit Facilities as a result of the issuance of the 2021 Notes and from the sale of the Home Health Business were pricing decrease triggering events that resulted in the interest rates reverting to the Eurodollar rate plus 5.25% or the base rate plus 4.25%.

In connection with the PIPE Transaction (see Note 4 - Stockholder’s Equity), the Company was required to use at least 75% of the net proceeds for the repayment of outstanding indebtedness. The Company repaid approximately $45.3 million of the Revolving Credit Facility indebtedness and accrued interest from those proceeds. In addition, the Company repaid $22.7 million of the Revolving Credit facility indebtedness from the net proceeds from the sale of the PBM Business.

As of December 31, 2016, the interest rate related to the Revolving Credit Facility is approximately 8.00% and the interest rate related to the Term Loan Facilities is approximately 6.50%. The interest rates may vary in the future depending on the Company’s consolidated net leverage ratio.

The Revolving Credit Facility matures on July 31, 2018 at which time all principal amounts outstanding are due and payable. The Term Loan Facilities require quarterly principal repayments of $3.1 million beginning March 31, 2016 until their July 31, 2020 maturity at which time the remaining principal amount of approximately $166.3 million is due and payable (see Note 17).

At December 31, 2016, the Company had an outstanding amount of $55.3 million drawn, with no additional borrowing capacity, under its Revolving Credit Facility after considering outstanding letters of credit totaling $4.6 million.

2021 Notes

On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company. The 2021 Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act pursuant to an Indenture (the “2021 Notes Indenture”), dated February 11, 2014, by and among the Company, the guarantors named therein and U.S. Bank National Association, as trustee.

Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually, in arrears, on February 15 and August 15 of each year, commencing on August 15, 2014. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.

The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of December 31, 2016, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.

The Company may redeem some or all of the 2021 Notes prior to February 15, 2017 by paying a “make-whole” premium. The Company may redeem some or all of the 2021 Notes on or after February 15, 2017 at specified redemption prices. In addition, prior to February 15, 2017, the Company may redeem up to 35% of the 2021 Notes with the net proceeds of certain equity offerings at a price of 108.88% plus accrued and unpaid interest, if any. The Company is obligated to offer to repurchase the 2021 Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events. These restrictions and prohibitions are subject to certain qualifications and exceptions.

The 2021 Notes Indenture contains covenants that, among other things, limit the Company’s ability and the ability of certain of the Company’s subsidiaries to (i) grant liens on its assets, (ii) make dividend payments, other distributions or other restricted payments, (iii) incur restrictions on the ability of the Company’s restricted subsidiaries to pay dividends or make other payments, (iv) enter into sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of substantially all of their assets, (vi) incur additional indebtedness, (vii) make investments, (viii) sell assets, including capital stock of subsidiaries, (ix) use the proceeds from sales of assets, including capital stock of restricted subsidiaries, and (x) enter into transactions with affiliates. In addition, the 2021 Notes Indenture requires, among other things, the Company to provide financial and current reports to holders of the 2021 Notes or file such reports electronically with the U.S. Securities and Exchange Commission (the “SEC”). These covenants are subject to a number of exceptions, limitations and qualifications set forth in the 2021 Notes Indenture.

Pursuant to the terms of the Second Amendment to the Senior Credit Facilities, the Company used the net proceeds of the 2021 Notes of approximately $194.5 million to repay $59.3 million of the Revolving Credit Facility and $135.2 million of the Term Loan Facilities.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ:



Financial Instrument	Carrying Value as of December 31, 2016		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Term Loan Facilities	$	210,207	$	—	$	195,493	$	—
2021 Notes	196,670		—		147,502		—
Total	$	406,877	$	—	$	342,995	$	—

The fair value hierarchy for disclosure of fair value measurements is as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.

Level 3: Inputs that are unobservable for the assets or liabilities.

Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.

Deferred Financing Costs

In connection with the Senior Credit Facilities and the 2021 Notes, the Company incurred underwriting fees, agent fees, legal fees and other expenses of approximately $24.6 million and $0.5 million, respectively. The deferred financing costs are reflected as additional issuance costs and amortized as an adjustment of interest expense over the remaining term of the Senior Credit Facilities using the effective interest method.

Future Maturities

The estimated future maturities of the Company’s long-term debt, inclusive of $12.5 million in deferred financing costs and $3.3 million of unamortized discount on the 2021 notes, as of December 31, 2016, are as follows (in thousands):



Year Ending December 31,	Amount
2017	$	22,315
2018	59,599
2019	13,053
2020	172,749
2021	200,000
Thereafter	—
Total future maturities	$	467,716

Interest Expense

The weighted average interest rate on the Company’s short-term borrowings under its Revolving Credit Facility during the years ended December 31, 2016 and 2015 was 10.3% and 11.7%, respectively.

Liquidity

As of the filing of this Annual Report, we expect that our cash on hand, proceeds from the priming credit agreement, proceeds from the private placement, and cash from operations will be sufficient to fund our anticipated working capital, scheduled principal and interest repayments and other cash needs for at least the next 12 months.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Breach of Contract Litigation in the Delaware Court of Chancery

On November 3, 2015, Walgreen Co. and various affiliates (“Walgreens”) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the “Defendants”). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries. The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the case. Walgreens filed an answering brief on January 11, 2016 and the Defendants filed a reply on January 25, 2016. On March 11, 2016, the Court held oral argument on the Company’s motion to dismiss and granted the motion, holding that Walgreens’ breach of contract claims for money damages must be resolved in accordance with the 2012 Purchase Agreement’s alternative dispute resolution procedure. On March 15, 2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court at that time, but instead would engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not grant Walgreens any other relief or enjoin the Company from taking any action. On December 8, 2016, the parties submitted the dispute to an arbitrator. On December 28, 2016, the arbitrator rendered its decision, finding that the Company had not violated the non-compete, except for certain limited sales of oral oncology, HIV and transplant pharmaceuticals, constituting approximately 3 percent of the total sales that Walgreens claimed were made in violation of the agreement. The arbitrator also concluded that Walgreens was not entitled to recover its lost profits or lost revenues as a result of any such sales. Despite that ruling, the arbitrator awarded Walgreens $5.8 million in damages, or approximately 20 percent of the total amount requested. The Company believes that arbitrator’s damages award ignored applicable law, contradicted the arbitrator’s liability findings and exceeded the scope of the arbitrator’s authority in light of both parties’ arbitration submissions. Accordingly, on January 13, 2017, the Company filed a motion to vacate the arbitration award. On February 10, 2017, Walgreens opposed the Company’s motion and filed a motion to confirm the arbitration award. The Company intends to continue to vigorously defend itself. Due to the inherent uncertainty in litigation, however, the Company can provide no assurance that its challenge to the award will be successful.

McCormack Shareholder Class Action Litigation in the Delaware Court of Chancery

On September 8, 2015, Thomas McCormack (the “Plaintiff”) filed a complaint in the Court of Chancery of the State of Delaware against the Company, the Board, and SunTrust Bank (“SunTrust”), as administrative agent, captioned Thomas McCormack v. BioScrip, Inc. et al., C.A. No. 11480-CB, alleging that the adoption of what the Plaintiff referred to as a “Proxy Put” or “Dead Hand Proxy Put” in the Company’s July 31, 2013 credit agreement (the “Credit Agreement”), as amended from time to time, constituted a breach of the Board’s fiduciary duty. Among other things, the Plaintiff sought a declaration that the Proxy Put was invalid, unenforceable, and severable from the Credit Agreement. While the Company and SunTrust deny completely all of the allegations of wrongdoing in the complaint, on October 9, 2015, the requisite lenders approved, and the Company and SunTrust executed, the Fifth Amendment to eliminate the so-called “Dead Hand Proxy Put.” As a result of the amendment, the Plaintiff agreed that his claims were moot, and the Company agreed to pay $130,000 in fees and expenses to the Plaintiff’s counsel. On January 14, 2016, the Court entered a Stipulation and Order (the “Order”) providing that the Plaintiff’s action will be dismissed with prejudice only as to the Plaintiff and the case will be closed. The Court has not passed on the amount of fees and expenses. The Company filed an affidavit notifying the Court of its compliance with the Order, which resulted in the action being dismissed and the case closed.

Derivative Lawsuit in the Delaware Court of Chancery

On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery (the “Derivative Complaint”) by the Park Employees’ & Retirement Board Employees’ Annuity & Benefit Fund of Chicago (the “Derivative Plaintiff”). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the “Director Defendants”), certain current and former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the “Officer Defendants”), Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as Park Employees and Retirement Board Employees’ Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015).

The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company’s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys’ fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from In re BioScrip, Inc., Securities Litigation (described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016. On May 31, 2016, the court determined that the Derivative Plaintiff’s claims could not proceed as pled but granted the Derivative Plaintiff thirty days in which to make a motion to amend the Derivative Complaint. The court reserved decision on the motion to dismiss and on June 29, 2016, the Derivative Plaintiff filed a motion for leave to file an amended complaint. On October 10, 2016, all defendants moved to dismiss the amended complaint and the Court heard oral argument on January 19, 2017.

The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources.

United States Attorney’s Office for the Southern District of New York and New York State Attorney General investigation

Effective January 8, 2014, the Company entered into the Federal Settlement Agreement with the U.S. Department of Justice (the “DOJ”) and David M. Kester (the “Relator”). The Federal Settlement Agreement represented the federal and private component of the Company’s agreement to settle all civil claims under the False Claims Act and related statutes and all common law claims (collectively, the “Claims”) that could have been brought by the DOJ and Relator in the qui tam lawsuit filed in the Southern District of New York (the “SDNY”) by the Relator relating to the distribution of the Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) by the Company’s legacy specialty pharmacy division (the “Legacy Division”) that was divested in May 2012 (the “Civil Action”). Until January 8, 2014, the Company was prohibited from publicly disclosing any information related to the existence of the Civil Action. On January 8, 2014, the Civil Action was unsealed and made public on order of the court. Effective February 11, 2014, the Company entered into the State Settlement Agreements with the Settling States. The State Settlement Agreements represented the state component of the Company’s agreement to settle the Claims that could have been brought by the Settling States that arose out of the Legacy Division’s distribution of the Medication.

With the execution of the Federal Settlement Agreement and the State Settlement Agreements (collectively, the “Settlement Agreements”), the Civil Action has been fully resolved, and the Company also expects to be fully resolved the federal and state claims that were or could have been raised in the Civil Action. All federal claims and all state claims by the Settling States that have been or could be brought against it in the Civil Action have been dismissed with prejudice. The State Settlement Agreements expressly recognize and affirmatively provide that, by entering into the State Settlement Agreements, the Company has not made any admission of liability and the Company expressly denies the allegations in the Civil Action.

Under the Settlement Agreements, the Company paid an aggregate of $15.0 million, plus interest (at an annual rate of 3.25%) in three annual payments from January 2014 through January 2016, of which the remaining $6.2 million, including interest, and $0.2 million of fees to the Relator was paid in January 2016. The Settlement Agreements represented a compromise to avoid the costs, distraction and uncertainty of protracted litigation. The Settlement Agreements do not include any admission of wrongdoing, illegal activity, or liability by the Company or its employees, directors, officers or agents.

During the year ended December 31, 2013, the Company included in its results of discontinued operations an accrual of $15.0 million in connection with the government’s investigation regarding certain operations of the Legacy Division. In January 2016, the Company paid $6.2 million, including interest, related to the Settlement Agreements and $0.2 million of fees to the Relator.

Securities Class Action Litigation in the Southern District of New York

On September 30, 2013, a putative securities class action lawsuit was filed in the United States District Court for the Southern District of New York (“SDNY”) against the Company and certain of its officers on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 20, 2013, inclusive.

On November 15, 2013, a putative securities class action lawsuit was filed in SDNY against the Company and certain of its directors and officers and certain underwriters in the Company’s April 2013 underwritten public offering of its common stock, on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 23, 2013, inclusive.

On December 19, 2013, the SDNY entered an order consolidating the two class action lawsuits as In re BioScrip, Inc., Securities Litigation, No. 13-cv-6922 (AJN) and appointing an interim lead plaintiff. The Company denies any allegations of wrongdoing in the consolidated class action lawsuit. The lead plaintiff filed a consolidated complaint on February 19, 2014 against the Company, certain of its directors and officers, certain underwriters in the Company’s April 2013 underwritten public offering of its common stock, and a certain stockholder of the Company. The consolidated complaint is brought on behalf of a putative class of purchasers of the Company’s securities between November 9, 2012 and November 6, 2013, inclusive, and persons and entities who purchased the Company’s securities pursuant or traceable to two underwritten public offerings of the Company’s common stock conducted in April 2013, and August 2013. The consolidated complaint alleges generally that the defendants made material misstatements and/or failed to disclose matters related to the Legacy Division’s distribution of Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) as well as the Company’s PBM Services segment. The consolidated complaint asserts claims under Sections 11, 12(a)(2) and 15 of the Securities Act and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated thereunder. All defendants in the case moved to dismiss the consolidated complaint on April 28, 2014. On March 31, 2015, the SDNY granted in part and denied in part the defendants’ motions to dismiss. On April 14, 2015, a motion to reconsider a portion of the denial of the motions to dismiss was filed on behalf of all the remaining defendants. Plaintiffs filed their opposition to that motion on April 28, 2015. On June 5, 2015, the SDNY denied the defendants’ motion to reconsider.

On September 25, 2015, the parties entered mediation concerning all pending claims. In October 2015, the parties reached an agreement in principle to settle all claims in the action (the “Proposed Settlement”), the terms and conditions of which were filed with the SDNY on December 18, 2015. The Company has agreed to the Proposed Settlement without any admission of liability or wrongdoing and solely in order to avoid the costs, distraction, and uncertainty of litigation.

On February 11, 2016, the Court granted preliminary approval for the settlement, certified a class of plaintiffs for settlement only, approved of the form of and mailing of notice to the stockholder class, and scheduled a final fairness hearing for June 13, 2016. Following preliminary approval, in accordance with the terms of the Proposed Settlement, the Company and its insurance carriers paid the amount of the settlement into an escrow fund. The Company’s contribution was not material, and the Company does not believe the contribution will have a material effect on results of operations, financial position, liquidity or capital resources.

On June 16, 2016, the Court granted final approval for the settlement. As a result, this case has now been dismissed with prejudice.

Government Regulation

Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company’s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.

From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s Consolidated Financial Statements.

Leases

The Company leases its facilities and certain equipment under various operating leases with third parties. The majority of these leases contain escalation clauses that increase base rent payments based upon either the Consumer Price Index or an agreed upon schedule.

In addition, the Company utilizes capital leases agreements with third parties to obtain certain assets such as telecommunications equipment and vehicles. Interest rates on capital leases are both fixed and variable and range from 3% to 7%.

As of December 31, 2016, future minimum lease payments under operating and capital leases were as follows (in thousands):



	Operating Leases		Capital Leases		Total
2017	$	8,125	$	766	$	8,891
2018	5,813		749		6,562
2019	3,371		503		3,874
2020	1,914		387		2,301
2021	593		—		593
2022 and Thereafter	577		—		577
Total Future Minimum Lease Payments	$	20,393	$	2,405	$	22,798

Rent expense for leased facilities and equipment was approximately $7.3 million, $7.2 million and $7.6 million for the years ended December 31, 2016, 2015 and 2014, respectively.

Purchase Commitments

As of December 31, 2016, the Company had commitments to purchase prescription drugs from drug manufacturers of approximately $38 million in 2017. These purchase commitments are made at levels expected to be used in the normal course of business.

CONCENTRATION OF RISK	12 Months Ended
CONCENTRATION OF RISK	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentration of Risk	CONCENTRATION OF RISK Customer and Credit Concentration Risk The Company provides trade credit to its customers in the normal course of business. One commercial payor, United Healthcare, accounted for approximately 24%, 26% and 22% of revenue during the years ended December 31, 2016, 2015 and 2014, respectively. Medicare accounted for 8%, 7% and 11% of revenue during the years ended December 31, 2016, 2015 and 2014, respectively. Therapy Revenue Concentration Risk The Company sells products related to the Immune Globulin (IG) therapy, which represented 19%, 17%, and 17% of revenue during the years ended December 31, 2016, 2015 and 2014, respectively.

INCOME TAXES

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company’s federal and state income tax provision (benefit) from continuing operations is summarized in the following table (in thousands):



	Year Ended December 31,
	2016			2015			2014
Current
Federal	$	—		$	—		$	(886	)
State	(30		)	(76		)	(41		)
Total current	(30		)	(76		)	(927		)
Deferred
Federal	1,744			(18,293		)	9,951
State	301			(3,163		)	2,169
Total deferred	2,045			(21,456		)	12,120
Total tax provision (benefit)	$	2,015		$	(21,532	)	$	11,193

The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):



	December 31,
	2016			2015
Deferred tax assets:
Reserves not currently deductible	$	19,249		$	27,467
Net operating loss carryforwards	121,084			91,350
Goodwill and intangibles (tax deductible)	27,549			34,983
Accrued expenses	467			654
Property basis differences	2,578			1,021
Stock based compensation	6,887			8,245
Other	638			715
Total deferred tax assets	178,452			164,435
Deferred tax liabilities:
Indefinite-lived goodwill and intangibles	(2,281		)	(236		)
Less: valuation allowance	(178,452		)	(164,435		)
Net deferred tax liability	(2,281		)	(236		)
Deferred taxes	$	(2,281	)	$	(236	)

The Company continually assesses the necessity of a valuation allowance. Based on this assessment, the Company concluded that a valuation allowance, in the amount of $178.5 million and $164.4 million, was required as of December 31, 2016 and 2015, respectively. If the Company determines in a future period that it is more likely than not that part or all of the deferred tax assets will be realized, the Company will reverse part or all of the valuation allowance.

At December 31, 2016, the Company had federal net operating loss (“NOL”) carryforwards of approximately $320.6 million, of which $15.6 million is subject to an annual limitation, which will begin expiring in 2026 and later. Of the Company’s $320.6 million federal NOLs, $18.2 million will be recorded in additional paid-in capital when realized as these NOLs are related to the exercise of non-qualified stock options and restricted stock grants. The Company has post-apportioned state NOL carryforwards of approximately $366.2 million, the majority of which will begin expiring in 2017 and later.

The Company’s reconciliation of the statutory rate to the effective income tax rate from continuing operations is as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Tax (benefit) at statutory rate	$	(11,275	)	$	(113,736	)	$	(48,554	)
State tax (benefit), net of federal taxes	(1,322		)	(8,356		)	(3,959		)
Valuation allowance changes affecting income tax expense	14,017			57,023			63,641
Change in tax contingencies	(66		)	(37		)	(109		)
Goodwill impairment	—			43,362			—
Other	661			212			174
Tax provision (benefit)	$	2,015		$	(21,532	)	$	11,193

As of December 31, 2016, the Company had $1.0 million of gross unrecognized tax benefits, of which $0.1 million, if recognized, would favorably affect the effective income tax rate in future periods. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Unrecognized tax benefits balance at January 1,	$	1,067		$	1,096		$	1,172
Lapse of statute of limitations	(46		)	(29		)	(76		)
Unrecognized tax benefits balance at December 31,	$	1,021		$	1,067		$	1,096

The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of income tax expense in the Consolidated Statements of Operations. As of December 31, 2016 the Company had a nominal amount of accrued interest related to uncertain tax positions. As of December 31, 2015, the Company had approximately $0.1 million of accrued interest related to uncertain tax positions.

The Company files income tax returns, including returns for its subsidiaries, with federal, state and local jurisdictions. The Company’s uncertain tax positions are related to tax years that remain subject to examination. As of December 31, 2016, U.S. tax returns for the years 2012 through 2015 remain subject to examination by federal tax authorities. Tax returns for the years 2011 through 2015 remain subject to examination by state and local tax authorities for a majority of the Company's state and local filings.

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

STOCK-BASED COMPENSATION

BioScrip Equity Incentive Plans

Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARS are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company's Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.

On May 8, 2014, the Company’s stockholders (i) approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 2,500,000 shares (the “2014 Additional Shares”) to 9,355,000 shares and to clarify that cash dividends or dividend equivalents may not be paid to holders of unvested restricted stock units, restricted stock grants and performance units until such awards are vested and non-forfeitable; and (ii) re-approved the material terms of the performance goals that are a part of the 2008 Plan. On September 19, 2014, the Company filed a Registration Statement on Form S-8 to register the issuance of the 2014 Additional Shares that were approved by the Company’s stockholders on May 8, 2014.

On November 30, 2016, the Company’s stockholders approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 5,250,000 shares (the “2016 Additional Shares”) to 14,605,000 shares. As of December 31, 2016, there were 6,775,475 shares that remained available for grant under the 2008 Plan.

Employee Stock Purchase Plan

On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP Plan is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP.

As of December 31, 2016, there were 319,070 shares that remained available for grant under the ESPP. During the year ended December 31, 2016, the ESPP’s third-party service provider purchased 245,371 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP, and the Company recorded $0.1 million of expense related to the ESPP.

BioScrip/CHS Equity Plan

In connection with the May 8, 2014 amendment to the 2008 Plan noted above, the Company determined to cease issuance of awards under the BioScrip/CHS 2006 Equity Incentive Plan. As of December 31, 2016, no shares remained available under the BioScrip/CHS Plan.

Stock Options

Options granted under the Equity Compensation Plans: (a) typically vest over a three-year period and, in certain instances, fully vest upon a change in control of the Company, (b) have an exercise price that may not be less than 100% of its fair market value on the date of grant and (c) are generally exercisable for ten years after the date of grant, subject to earlier termination in certain circumstances.

Option expense is amortized on a straight-line basis over the requisite service period. The Company recognized compensation expense related to stock options of $3.4 million, $4.8 million, and $6.9 million, in the years ended December 31, 2016, 2015 and 2014, respectively.

The weighted-average, grant-date fair value of options granted during the years ending December 31, 2016, 2015 and 2014 was $0.72, $2.25, and $4.32, respectively. The fair value of stock options granted was estimated on the date of grant using a binomial model for grants issued through June 30, 2015 and a Black-Scholes option-pricing model for grants issued beginning July 1, 2015. The assumptions used to compute the fair value of options for the years ending December 31, 2016, 2015 and 2014 were:



	2016		2015		2014
Expected volatility	68.1	%	62.3	%	61.0	%
Risk-free interest rate	1.98	%	2.20	%	2.50	%
Expected life of options	4.8 years		8.9 years		5.7 years
Dividend rate	—		—		—

A summary of stock option activity for the Equity Compensation Plans through December 31, 2016 was as follows:



	Options		Weighted Average Exercise Price		Aggregate Intrinsic Value (thousands)		Weighted Average Remaining Contractual Life
Balance at December 31, 2015	6,635,597		$	6.46	$	1.6	5.8 years
Granted	562,810		$	1.26	$	—
Exercised	—		$	—	$	—
Forfeited and expired	(1,933,037	)	$	6.79	$	—
Balance at December 31, 2016	5,265,370		$	5.78	$	—	4.4 years
Outstanding options less expected forfeitures at December 31, 2016	5,132,477		$	5.85	$	—	4.3 years
Exercisable at December 31, 2016	4,035,588		$	6.68	$	—	3.3 years

Cash received from option exercises under share-based payment arrangements was nominal for the years ended December 31, 2016 and 2015, and $1.5 million for the year ended December 31, 2014.

The maximum term of stock options under these plans is ten years. Options outstanding as of December 31, 2016 expire on various dates ranging from January 2017 through March 2026. The following table outlines our outstanding and exercisable stock options as of December 31, 2016:



	Options Outstanding				Options Exercisable
Range of Option Exercise Price	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Options Exercisable	Weighted Average Exercise Price
$0.00 - $2.06	552,810	$	1.19	6.0 years	110,000	$	1.53
$2.06 - $4.13	1,350,984	$	2.67	5.8 years	801,680	$	2.73
$4.13 - $6.19	572,000	$	4.84	4.7 years	464,334	$	4.75
$6.19 - $8.25	1,898,576	$	7.06	3.4 years	1,768,574	$	7.01
$8.25 - $10.32	252,500	$	9.09	1.0 year	252,500	$	9.09
$10.32 - $12.38	305,000	$	11.04	5.0 years	305,000	$	11.04
$12.38 - $14.41	325,500	$	12.92	2.9 years	325,500	$	12.92
$16.50 - $18.57	8,000	$	16.63	6.6 years	8,000	$	16.63
All options	5,265,370	$	5.78	4.4 years	4,035,588	$	6.68

As of December 31, 2016 there was $1.4 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 2.0 years.

As compensation expense for options granted is recorded over the requisite service period of options, future stock-based compensation expense may be greater as additional options are granted.

Restricted Stock

Under the Equity Compensation Plans, stock grants subject solely to an employee’s or director’s continued service with the Company will not become fully vested less than (a) three years from the date of grant to employees and, in certain instances, may fully vest upon a change in control of the Company, and (b) one year from the date of grant for directors. Stock grants subject to the achievement of performance conditions will not vest less than one year from the date of grant. Such performance shares may vest after one year from grant. No such time restrictions applied to stock grants made under the Company’s prior equity compensation plans.

The Company recognized compensation expense related to restricted stock awards of $0.5 million, $0.4 million, and $1.6 million for the years ended December 31, 2016, 2015 and 2014, respectively.

Since the Company records compensation expense for restricted stock awards based on the vesting requirements, which generally includes time elapsed, market conditions and/or performance conditions, the weighted average period over which the expense is recognized varies. Also, future equity-based compensation expense may be greater if additional restricted stock awards are made.

A summary of restricted stock award activity through December 31, 2016 was as follows:



	Restricted Stock		Weighted Average Grant Date Fair Value		Weighted Average Remaining Recognition Period
Balance at December 31, 2015	49,998		$	11.89	2.2 years
Granted	575,858		$	1.63
Awards Vested	(78,500	)	$	2.59
Canceled	—		$	—
Balance at December 31, 2016	547,356		$	2.43	2.2 years

As of December 31, 2016, there was $0.5 million in unrecognized compensation expense related to unvested restricted stock awards. The total grant date fair value of awards vested during the years ended December 31, 2016, 2015 and 2014 was $0.9 million, $0.2 million, and $3.5 million, respectively. The total fair value of restricted stock awards vested during the years December 31, 2016, 2015 and 2014 was $0.2 million, $0.5 million, and $2.0 million, respectively.

Performance Units

Under the 2008 Plan, the Compensation Committee may grant performance units to key employees. The Compensation Committee will establish the terms and conditions of any performance units granted, including the performance goals, the performance period and the value for each performance unit. If the performance goals are satisfied, the Company would pay the key employee an amount in cash equal to the value of each performance unit at the time of payment. In no event may a key employee receive an amount in excess of $1.0 million with respect to performance units for any given year. As of December 31, 2016, 377,358 performance units have been granted under the 2008 Plan.

Stock Appreciation Rights

The Company has outstanding cash-based phantom stock appreciation rights (“SARs”), which are independent of the Company's 2008 Equity Incentive Plan, with respect to 300,000 shares of the Company's common stock. The SARs vest in three equal annual installments and will fully vest in connection with a change of control (as defined in the grantee’s employment agreement). The SARs may be exercised, in whole or in part, to the extent each SAR has been vested and will receive in cash the amount by which the closing stock price on the exercise date exceeds the Grant Price, if any. Upon the exercise of any SARs, as soon as practicable under the applicable federal and state securities laws, the grantee may be required to use the net after-tax proceeds of such exercise to purchase shares of the Common Stock from the Company at the closing stock price of the Common Stock on that date and hold such shares of Common Stock for a period of not less than one year from the date of purchase, except that the grantee will not be required to purchase any shares of Common Stock if the SAR is exercised on or after a change of control of the Company. The grantee’s right to exercise the SAR will expire on the earliest of (1) the tenth anniversary of the grant date, or (2) under certain conditions as a result of termination of the grantee’s employment.

A summary of SAR activity through December 31, 2016 was as follows:



	Stock Appreciation Rights	Weighted Average Exercise Price		Weighted Average Remaining Recognition Period
Balance at December 31, 2015	300,000	$	6.48	0.0 years
Granted	—	$	—
Exercised	—	$	—
Canceled	—	$	—
Balance at December 31, 2016	300,000	$	6.48	0.0 years

The SARs are recorded as a liability in other non-current liabilities in the accompanying Consolidated Balance Sheets. Compensation benefit related to the SARs for the year ended December 31, 2016, 2015 and 2014 was $0.1 million, $0.9 million and negligible. As of December 31, 2016 all outstanding SARs were fully vested. In addition, because they are settled with cash, the fair value of the SAR awards is revalued on a quarterly basis. During the years ended December 31, 2016, 2015 and 2014, the Company did not pay cash related to the exercise of SAR awards.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

DEFINED CONTRIBUTION PLAN	12 Months Ended
DEFINED CONTRIBUTION PLAN	Dec. 31, 2016
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Defined Contribution Plan	DEFINED CONTRIBUTION PLAN The Company maintains a deferred compensation plan under Section 401(k) of the Internal Revenue Code. Under the Plan, employees may elect to defer up to 100% of their salary, subject to Internal Revenue Service limits, and the Company may make a discretionary matching contribution. The Company recorded matching contributions within general and administrative expenses in the Consolidated Statements of Operations of $1.3 million and $1.6 million during the years ended December 31, 2015 and 2014, respectively. The Company elected to forgo a matching contribution during the year ended December 31, 2016.

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Financial Data (Unaudited)

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

A summary of unaudited quarterly financial information for the years ended December 31, 2016 and 2015 is as follows (in thousands except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year ended December 31, 2016
Revenue	$	238,462		$	232,462		$	224,542		$	240,123
Gross profit	64,232			64,164			62,585			74,650
Loss from continuing operations, before income taxes	(9,747		)	(8,160		)	(10,669		)	(3,776		)
Net income (loss) from discontinued operations, net of income taxes	233			75			(174		)	(7,273		)
Net loss	$	(9,537	)	$	(8,234	)	$	(11,264	)	$	(12,471	)

Loss per share from continuing operations, basic and diluted	$	(0.17	)	$	(0.14	)	$	(0.12	)	$	(0.06	)
Loss per share from discontinued operations, basic and diluted	—			—			—			(0.06		)
Loss per share, basic and diluted	$	(0.17	)	$	(0.14	)	$	(0.12	)	$	(0.12	)

Year ended December 31, 2015
Revenue	$	244,357		$	246,897		$	247,224		$	243,745
Gross profit	64,955			64,818			65,233			65,909
Loss from continuing operations, before income taxes	(15,367		)	(264,822		)	(28,791		)	(15,980		)
Net income (loss) from discontinued operations, net of income taxes	(2,379		)	94			7,457			(1,451		)
Net loss	$	(19,674	)	$	(244,807	)	$	(16,783	)	$	(18,443	)

Loss per share from continuing operations, basic and diluted	$	(0.28	)	$	(3.62	)	$	(0.38	)	$	(0.27	)
Income (loss) per share from discontinued operations, basic and diluted	(0.03		)	—			0.11			(0.02		)
Loss per share, basic and diluted	$	(0.31	)	$	(3.62	)	$	(0.27	)	$	(0.29	)

With the sale of the PBM Business on August 27, 2015 (see Note 6 - Discontinued Operations), the preceding prior period financial information includes reclassifications to prior period financial statements to include the PBM Business as discontinued operations.

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS On January 6, 2017, the Company entered into a sixth amendment (the “Sixth Amendment”) to its credit agreement dated as of July 31, 2013, with SunTrust Bank (“SunTrust”), Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., as amended on December 23, 2013, January 31, 2014, March 1, 2015, August 6, 2015 and October 9, 2015 (the “Senior Credit Facilities”). The Sixth Amendment amended the Senior Credit Facilities to, among other things, (a) permanently reduce the revolving commitments in accordance with a schedule set forth therein and prohibit further revolving borrowings, (b) require the cash collateralization of letters of credit issued thereunder, (c) increase the interest rate for loans outstanding under the Senior Credit Facilities and require a portion of accrued interest at the increased rate to be paid-in-kind, (d) permit the Company and its subsidiaries to enter into the Priming Credit Agreement (as defined below), which provides the Company with an aggregate borrowing commitment of $25,000,000, to be fully drawn at closing, and permit the Company to incur the obligations thereunder and to subordinate the liens securing the Senior Credit Facilities to the liens securing the obligations under the Priming Credit Agreement, and (e) amend certain covenants, including by (i) increasing the consolidated senior secured net leverage ratio covenant, (ii) adding a minimum EBITDA covenant, to be tested quarterly, and (iii) otherwise restricting the ability of the Company and its subsidiaries to incur certain additional indebtedness and make additional significant investments or acquisitions. On January 6, 2017, the Company entered into a new credit agreement (the “Priming Credit Agreement”) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provides an aggregate borrowing commitment of $25,000,000, which will be fully drawn at closing. The Company intends to use the proceeds of the borrowing under the Priming Credit Agreement (i) to permanently prepay a portion of the outstanding revolving loan balance under the Senior Credit Facilities, (ii) to cash collateralize letters of credit issued under the Senior Credit Facilities, (iii) to pay fees and expenses in connection with the execution and delivery of the Priming Credit Agreement and the Sixth Amendment, and (iv) for working capital and other general corporate purposes. The Company will pay interest on the outstanding loans under the Priming Credit Agreement at a rate of 10% per annum, and accrued interest will be payable in cash monthly in arrears on the last day of each fiscal month. The obligations under the Priming Credit Agreement are not subject to scheduled amortization installments, and all outstanding obligations will mature and be due and payable in full in cash on July 31, 2018. The occurrence of certain events of default may increase the applicable rate of interest by 2% and could result in the acceleration of the Company’s obligations under the Priming Credit Agreement prior to stated maturity. The Priming Credit Agreement contains mandatory prepayments, representations and warranties, affirmative and negative covenants, financial covenants and events of default that are substantially identical to the corresponding provisions of the Senior Credit Facilities. In addition, the obligations under the Priming Credit Agreement are guaranteed by joint and several guarantees from the Company’s subsidiaries and secured by a security interest on substantially all of the assets of the Company and its subsidiaries. The payment obligations under the Priming Credit Agreement rank pari passu in right of payment with the payment obligations under the Senior Credit Facilities. Upon the occurrence of certain mandatory prepayment events, the Company is required to apply the net proceeds thereof, first, to the permanent prepayment of outstanding revolving loans under the Senior Credit Facilities until paid in full, next, to the permanent prepayment of outstanding term loans under the Senior Credit Facilities until paid in full, and, last, to the permanent prepayment of outstanding loans under the Priming Credit Agreement. On March 1, 2017, the Company entered into a Stock Purchase Agreement with Venor Capital Master Fund Ltd., Map 139 Segregated Portfolio of LMA SPC, Venor Special Situations Fund II LP and Trevithick LP (the “Stockholders”). Pursuant to the Purchase Agreement, the Company sold an aggregate of 3.3 million shares of its common stock (the “Shares”) for aggregate gross proceeds of approximately $5.1 million in a private placement transaction (the “Private Placement”). The purchase price for each Share was $1.5366, which was negotiated between the Company and the Purchasers based on the volume-weighted average price of the Company's common stock on the NASDAQ Global Market on March 1, 2017. In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within ten (10) days of the date it files its annual report on Form 10-K for the fiscal year ended December 31, 2016, for purposes of registering the resale of the Shares and any shares of common stock issued as a dividend or other distribution with respect to the Shares. The Company also agreed, among other things, to indemnify the selling holders under the registration statement from certain liabilities and to pay all fees and expenses (excluding underwriting discounts and selling commissions and legal fees) incident to the Company’s obligations under the Registration Rights Agreement. Proceeds from the Private Placement will be used for working capital and general corporate purposes.

Schedule II -- Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2016

Valuation and Qualifying Accounts [Abstract]

Schedule II -- Valuation and Qualifying Accounts

Bioscrip, Inc. and Subsidiaries

Schedule II-- Valuation and Qualifying Accounts

(in thousands)



	Balance at Beginning of Period		Write-Off of Receivables			Charged to Costs and Expenses		Balance at End of Period
Year ended December 31, 2014
Allowance for doubtful accounts	$	17,735	$	(30,877	)	$	79,547	$	66,405
Year ended December 31, 2015
Allowance for doubtful accounts	$	66,405	$	(47,758	)	$	41,042	$	59,689
Year ended December 31, 2016
Allowance for doubtful accounts	$	59,689	$	(41,758	)	$	26,799	$	44,730

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation

The Company’s Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

Consolidation

Use of Estimates

Fair Value Measurements


•	Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.


•	Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.


•	Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents.

Receivables

Allowance for Doubtful Accounts

Allowance for Contractual Discounts

Inventory

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	years	-	5	years
Office equipment				5	years
Vehicles	4	years	-	5	years
Medical equipment	13	months	-	5	years
Furniture and fixtures				5	years

Goodwill

Intangible Assets

Impairment of Long Lived Assets

Amounts due to Plan Sponsors

Financial Instruments

Accounting for Stock-Based Compensation

Recent Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Aging of net accounts receivable



	December 31, 2016							December 31, 2015
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	19,891	$	8,278	$	28,169		$	19,944	$	11,369	$	31,313
Commercial	97,744		19,848		117,592			94,477		20,213		114,690
Patient	3,955		6,825		10,780			5,014		6,025		11,039
Gross accounts receivable	$	121,590	$	34,951	156,541			$	119,435	$	37,607	157,042
Allowance for doubtful accounts					(44,730		)					(59,689		)
Net accounts receivable					$	111,811						$	97,353

Estimated useful lives of assets

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	years	-	5	years
Office equipment				5	years
Vehicles	4	years	-	5	years
Medical equipment	13	months	-	5	years
Furniture and fixtures				5	years

LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Computation of basic and diluted loss per common share

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Year Ended December 31,
	2016			2015			2014
Numerator:
Loss from continuing operations, net of income taxes	$	(34,367	)	$	(303,428	)	$	(149,920	)
(Loss) income from discontinued operations, net of income taxes	(7,139		)	3,721			2,452
Net loss	(41,506		)	(299,707		)	(147,468		)
Accrued dividends on Preferred Stock	(8,392		)	(6,120		)	—
Deemed dividends on Preferred Stock	(692		)	(3,690		)	—
Loss attributable to common stockholders	$	(50,590	)	$	(309,517	)	$	(147,468	)

Denominator - Basic and Diluted:
Weighted average number of common shares outstanding	93,740			68,710			68,476
Loss Per Common Share:
Loss from continuing operations, basic and diluted	$	(0.46	)	$	(4.56	)	$	(2.19	)
(Loss) income from discontinued operations, basic and diluted	(0.08		)	0.05			0.04
Loss per common share, basic and diluted	$	(0.54	)	$	(4.51	)	$	(2.15	)

STOCKHOLDERS' DEFICIT (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Attributable to Parent [Abstract]

Schedule of allocation of proceeds from the Purchase Agreement based on relative fair values

The proceeds from the Purchase Agreement were allocated among the instruments based on their relative fair values as follows (in thousands):



	Relative Fair Value Allocation
Financial instruments:	March 9, 2015
Series A Preferred Stock ¹	$	59,355
PIPE Warrants ²	3,145
Total Investment	$	62,500

Carrying value of Series A and C Preferred Stock

The following table sets forth the activity recorded during the year ended December 31, 2016 related to the Series A Preferred Stock (in thousands) issued for both the PIPE Transaction and the Rights Offering:



Series A Preferred Stock carrying value at December 31, 2015	$	62,918
Exchange of Series A for Series C	(60,776		)
Discount related to beneficial conversion feature	40
Dividends recorded through December 31, 2016 ¹	280
Series A Preferred Stock carrying value at December 31, 2016	$	2,462

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

The following table sets forth the activity recorded during the year ended December 31, 2016 related to the Series C Preferred Stock (in thousands):



Series C Preferred Stock carrying value at December 31, 2015	$	—
Exchange of shares - Series A to Series C	60,776
Accretion of discount related to issuance costs	652
Dividends recorded through December 31, 2016 ¹	8,112
Series C Preferred Stock carrying value at December 31, 2016	$	69,540

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Carrying value of Pipe Warrants

The following sets forth the carrying value of the PIPE Warrants which is classified as equity on the Consolidated Balance Sheet (in thousands):



	Carrying Value
PIPE Warrants	March 9, 2015
Fair value allocated to PIPE Warrants	$	3,145
Discount related to issuance costs	(203		)
Carrying value of PIPE Warrants	$	2,942

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Schedule of consideration transferred in acquisition

The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):



Cash	$	67,516
Equity issued at closing	9,938
Capital lease obligation assumed	301
Fair value of contingent consideration	15,400
Total consideration	$	93,155

Schedule of assets acquired and liabilities assumed

The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions as of September 9, 2016 (in thousands):



Accounts receivable	$	11,956
Inventories	3,199
Prepaids and other assets	852
Total current assets	$	16,007
Property and equipment	4,651
Goodwill	57,218
Managed care contracts	24,700
Licenses	5,400
Trade name	1,800
Non-compete agreements	200
Other long-term assets	891
Total assets	$	110,867
Accounts payable	14,576
Accrued liabilities	3,136
Total liabilities	$	17,712
Net assets acquired	$	93,155

Schedule of pro forma combined results



	Years Ended December 31,
Pro forma impact of acquisition (in millions, except for per share amounts):	2016			2015			2014
Revenues	$	1,019		$	1,091		$	1,028
Gross profit	$	288		$	289		$	277
Gross profit percentage	28.3		%	26.5		%	26.9		%
Loss from continuing operations, net of income taxes	$	(44	)	$	(322	)	$	(178	)
Basic loss per share from continuing operations	$	(0.47	)	$	(4.68	)	$	(2.60	)
Diluted loss per share from continuing operations	$	(0.47	)	$	(4.68	)	$	(2.60	)

Acquisition and integration expenses



	Year Ended December 31,
	2016		2015		2014
Legal and professional fees	$	3,059	$	1,033	$	6,931
Financial advisory fees	5,087		—		—
Employee costs including redundant salaries and benefits and severance	—		—		2,016
Facilities consolidation and discontinuation	1,323		488		1,401
Bad debt expense and contractual adjustments related to acquired accounts receivable	—		—		5,430
Legal settlement	—		—		334
Other	653		219		1,812
Total	$	10,122	$	1,740	$	17,924

DISCONTINUED OPERATIONS (Tables)

12 Months Ended

Dec. 31, 2016

Discontinued Operations and Disposal Groups [Abstract]

Summary of carrying value of net assets

As of the August 27, 2015 closing date of the sale of the PBM Business, the carrying value of the net assets of the PBM Business was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	7,163
Total current assets	7,163
Property and equipment, net	175
Goodwill	12,744
Total assets	20,082
Amounts due to plan sponsors	6,950
Total liabilities	6,950
Net assets	$	13,132

As of the March 31, 2014 closing date of the sale of the Home Health Business, the carrying value of the net assets of the Subject Companies was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	12,597
Prepaid expenses and other current assets	242
Total current assets	12,839
Property and equipment, net	402
Goodwill	33,784
Intangible assets	15,400
Other non-current assets	28
Total assets	62,453
Accounts payable	673
Amounts due to plan sponsors	229
Accrued expenses and other current liabilities	3,008
Total liabilities	3,910
Net assets	$	58,543

Summary of operating results

The operating results included in discontinued operations of the PBM Business for the years ended December 31, 2016, 2015 and 2014 are summarized as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Revenue	$	—		$	44,375		$	61,401
Gross profit	$	—		$	9,763		$	17,635
Other operating expenses	1,015			5,444			10,878
Bad debt expense	—			(45		)	27
(Loss) income from operations	(1,015		)	4,364			6,730
Gain on sale before income taxes	—			(11,424		)	—
Financial advisory fee and legal expenses	614			1,731			—
Other income and expenses, net	(326		)	1,898			(6		)
(Loss) income before income taxes	(1,303		)	12,159			6,736
Income tax expense	—			206			198
(Loss) income from discontinued operations, net of income taxes	$	(1,303	)	$	11,953		$	6,538

The operating results included in discontinued operations of the Home Health Business for the years ended December 31, 2016, 2015 and 2014 are summarized as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Revenue	$	—		$	—		$	18,551
Gross profit	$	—		$	—		$	6,918
Other operating expenses	—			417			8,219
Bad debt expense	—			—			902
Loss from operations	—			(417		)	(2,203		)
Gain on sale before income taxes	—			—			(2,067		)
Financial advisor fee and legal expenses	(44		)	—			2,875
Impairment of assets	—			—			452
Other costs and expenses	(118		)	861			47
Income (loss) before income taxes	162			(1,278		)	(3,510		)
Income tax expense (benefit)	—			—			(4,257		)
Income (loss) from discontinued operations, net of income taxes	$	162		$	(1,278	)	$	747



	Year Ended December 31,
	2016			2015			2014
Revenue	$	—		$	—		$	—
Gross profit	$	—		$	—		$	(439	)
Other operating expenses	185			4,485			3,995
Legal fees and settlement expense	2			1,312			—
Other (income) expense, including gain on sale	17			1,157			399
Loss from discontinued operations, net of income taxes	$	(204	)	$	(6,954	)	$	(4,833	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

+ Details

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in goodwill

Goodwill, and the changes in the carrying amount of goodwill for the years ended December 31, 2016 and 2015, are as follows (in thousands):



	Infusion Services
Balance at December 31, 2014	$	573,323
Impairment	(251,850		)
Disposition of PBM Services	(12,744		)
Balance at December 31, 2015	308,729
Acquisition of Home Solutions	57,218
Balance at December 31, 2016	$	365,947

Summary of intangible assets

Intangible assets consisted of the following as of December 31, 2016 and 2015 (in thousands):



	December 31, 2016							December 31, 2015
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite Lived Assets
Infusion customer relationships	$	25,650	$	(23,768	)	$	1,882	$	25,650	$	(20,789	)	$	4,861
Managed care contracts	24,700		(1,898		)	22,802		—		—			—
Licenses	5,400		(906		)	4,494		—		—			—
Trade name	1,800		(281		)	1,519		—		—			—
Non-compete agreements	1,700		(1,354		)	346		1,500		(1,233		)	267
	$	59,250	$	(28,207	)	$	31,043	$	27,150	$	(22,022	)	$	5,128

Finite lived intangible assets estimated useful lives

Finite lived intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:



	Estimated Useful Life
Infusion customer relationships	5	months		-	4	years
Managed care contracts					4	years
Licenses					2	years
Trade name					2	years
Non-compete agreements		1	year	-	5	years

Estimated amortization expense

Amortization expense is expected to be the following (in thousands):



Year ending December 31,	Estimated Amortization
2017	$	11,925
2018	8,821
2019	6,121
2020	4,176
2021	—
Thereafter	—
Total estimated amortization expense	$	31,043

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSE, NET (Tables)

12 Months Ended

Dec. 31, 2016

Restructuring and Related Activities [Abstract]

Schedule of restructuring, acquisition, integration, and other expenses, net



	Year Ended December 31,
	2016			2015		2014
Restructuring expense	$	10,334		$	22,635	$	19,646
Acquisition and integration expenses	10,122			1,740		17,924
Change in fair value of contingent consideration	(4,597		)	30		(7,364		)
Total restructuring, acquisition, integration, and other expenses, net	15,859			24,405		30,206

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and equipment

Property and equipment consists of the following (in thousands):



	December 31,
	2016			2015
Computer and office equipment	$	29,556		$	22,561
Software capitalized for internal use	16,481			15,600
Vehicles	2,552			1,938
Medical equipment	31,509			28,423
Work in progress	5,746			6,624
Furniture and fixtures	5,318			4,543
Leasehold improvements	16,464			14,285
Property and equipment, gross	107,626			93,974
Less: Accumulated depreciation	(75,091		)	(62,035		)
Property and equipment, net	$	32,535		$	31,939

DEBT (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Schedule of debt

As of December 31, 2016 and 2015, the Company’s debt consisted of the following (in thousands):



	December 31,
	2016			2015
Revolving Credit Facility	$	55,300		$	15,000
Term Loan Facilities	210,207			222,757
2021 Notes, net of unamortized discount	196,670			196,038
Capital leases	2,209			189
Less: Deferred financing costs	(12,452		)	(15,863		)
Total Debt	451,934			418,121
Less: Current portion	(18,521		)	(24,380		)
Long-term debt, net of current portion	$	433,413		$	393,741

Schedule of carrying value and estimated fair value differences

The following details our financial instruments where the carrying value and the fair value differ:



Financial Instrument	Carrying Value as of December 31, 2016		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Term Loan Facilities	$	210,207	$	—	$	195,493	$	—
2021 Notes	196,670		—		147,502		—
Total	$	406,877	$	—	$	342,995	$	—

Estimated future maturities of debt



Year Ending December 31,	Amount
2017	$	22,315
2018	59,599
2019	13,053
2020	172,749
2021	200,000
Thereafter	—
Total future maturities	$	467,716

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Future minimum lease payments under operating and capital leases

As of December 31, 2016, future minimum lease payments under operating and capital leases were as follows (in thousands):



	Operating Leases		Capital Leases		Total
2017	$	8,125	$	766	$	8,891
2018	5,813		749		6,562
2019	3,371		503		3,874
2020	1,914		387		2,301
2021	593		—		593
2022 and Thereafter	577		—		577
Total Future Minimum Lease Payments	$	20,393	$	2,405	$	22,798

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Federal and state income tax provision (benefit)

The Company’s federal and state income tax provision (benefit) from continuing operations is summarized in the following table (in thousands):



	Year Ended December 31,
	2016			2015			2014
Current
Federal	$	—		$	—		$	(886	)
State	(30		)	(76		)	(41		)
Total current	(30		)	(76		)	(927		)
Deferred
Federal	1,744			(18,293		)	9,951
State	301			(3,163		)	2,169
Total deferred	2,045			(21,456		)	12,120
Total tax provision (benefit)	$	2,015		$	(21,532	)	$	11,193

Effect of temporary differences that give rise to significant portion of deferred taxes

The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):



	December 31,
	2016			2015
Deferred tax assets:
Reserves not currently deductible	$	19,249		$	27,467
Net operating loss carryforwards	121,084			91,350
Goodwill and intangibles (tax deductible)	27,549			34,983
Accrued expenses	467			654
Property basis differences	2,578			1,021
Stock based compensation	6,887			8,245
Other	638			715
Total deferred tax assets	178,452			164,435
Deferred tax liabilities:
Indefinite-lived goodwill and intangibles	(2,281		)	(236		)
Less: valuation allowance	(178,452		)	(164,435		)
Net deferred tax liability	(2,281		)	(236		)
Deferred taxes	$	(2,281	)	$	(236	)

Reconciliation of the statutory rate to the effective income tax rate

The Company’s reconciliation of the statutory rate to the effective income tax rate from continuing operations is as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Tax (benefit) at statutory rate	$	(11,275	)	$	(113,736	)	$	(48,554	)
State tax (benefit), net of federal taxes	(1,322		)	(8,356		)	(3,959		)
Valuation allowance changes affecting income tax expense	14,017			57,023			63,641
Change in tax contingencies	(66		)	(37		)	(109		)
Goodwill impairment	—			43,362			—
Other	661			212			174
Tax provision (benefit)	$	2,015		$	(21,532	)	$	11,193

Reconciliation of beginning and ending amount of gross unrecognized tax benefits

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2016			2015			2014
Unrecognized tax benefits balance at January 1,	$	1,067		$	1,096		$	1,172
Lapse of statute of limitations	(46		)	(29		)	(76		)
Unrecognized tax benefits balance at December 31,	$	1,021		$	1,067		$	1,096

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Weighted-average assumptions

The assumptions used to compute the fair value of options for the years ending December 31, 2016, 2015 and 2014 were:



	2016		2015		2014
Expected volatility	68.1	%	62.3	%	61.0	%
Risk-free interest rate	1.98	%	2.20	%	2.50	%
Expected life of options	4.8 years		8.9 years		5.7 years
Dividend rate	—		—		—

Stock option activity

A summary of stock option activity for the Equity Compensation Plans through December 31, 2016 was as follows:



	Options		Weighted Average Exercise Price		Aggregate Intrinsic Value (thousands)		Weighted Average Remaining Contractual Life
Balance at December 31, 2015	6,635,597		$	6.46	$	1.6	5.8 years
Granted	562,810		$	1.26	$	—
Exercised	—		$	—	$	—
Forfeited and expired	(1,933,037	)	$	6.79	$	—
Balance at December 31, 2016	5,265,370		$	5.78	$	—	4.4 years
Outstanding options less expected forfeitures at December 31, 2016	5,132,477		$	5.85	$	—	4.3 years
Exercisable at December 31, 2016	4,035,588		$	6.68	$	—	3.3 years

Outstanding and exercisable stock options

The following table outlines our outstanding and exercisable stock options as of December 31, 2016:



	Options Outstanding				Options Exercisable
Range of Option Exercise Price	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Options Exercisable	Weighted Average Exercise Price
$0.00 - $2.06	552,810	$	1.19	6.0 years	110,000	$	1.53
$2.06 - $4.13	1,350,984	$	2.67	5.8 years	801,680	$	2.73
$4.13 - $6.19	572,000	$	4.84	4.7 years	464,334	$	4.75
$6.19 - $8.25	1,898,576	$	7.06	3.4 years	1,768,574	$	7.01
$8.25 - $10.32	252,500	$	9.09	1.0 year	252,500	$	9.09
$10.32 - $12.38	305,000	$	11.04	5.0 years	305,000	$	11.04
$12.38 - $14.41	325,500	$	12.92	2.9 years	325,500	$	12.92
$16.50 - $18.57	8,000	$	16.63	6.6 years	8,000	$	16.63
All options	5,265,370	$	5.78	4.4 years	4,035,588	$	6.68

Restricted stock award activity

A summary of restricted stock award activity through December 31, 2016 was as follows:



	Restricted Stock		Weighted Average Grant Date Fair Value		Weighted Average Remaining Recognition Period
Balance at December 31, 2015	49,998		$	11.89	2.2 years
Granted	575,858		$	1.63
Awards Vested	(78,500	)	$	2.59
Canceled	—		$	—
Balance at December 31, 2016	547,356		$	2.43	2.2 years

SAR activity

A summary of SAR activity through December 31, 2016 was as follows:



	Stock Appreciation Rights	Weighted Average Exercise Price		Weighted Average Remaining Recognition Period
Balance at December 31, 2015	300,000	$	6.48	0.0 years
Granted	—	$	—
Exercised	—	$	—
Canceled	—	$	—
Balance at December 31, 2016	300,000	$	6.48	0.0 years

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2016

Selected Quarterly Financial Information [Abstract]

Schedule of Quarterly Financial Information

A summary of unaudited quarterly financial information for the years ended December 31, 2016 and 2015 is as follows (in thousands except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year ended December 31, 2016
Revenue	$	238,462		$	232,462		$	224,542		$	240,123
Gross profit	64,232			64,164			62,585			74,650
Loss from continuing operations, before income taxes	(9,747		)	(8,160		)	(10,669		)	(3,776		)
Net income (loss) from discontinued operations, net of income taxes	233			75			(174		)	(7,273		)
Net loss	$	(9,537	)	$	(8,234	)	$	(11,264	)	$	(12,471	)

Loss per share from continuing operations, basic and diluted	$	(0.17	)	$	(0.14	)	$	(0.12	)	$	(0.06	)
Loss per share from discontinued operations, basic and diluted	—			—			—			(0.06		)
Loss per share, basic and diluted	$	(0.17	)	$	(0.14	)	$	(0.12	)	$	(0.12	)

Year ended December 31, 2015
Revenue	$	244,357		$	246,897		$	247,224		$	243,745
Gross profit	64,955			64,818			65,233			65,909
Loss from continuing operations, before income taxes	(15,367		)	(264,822		)	(28,791		)	(15,980		)
Net income (loss) from discontinued operations, net of income taxes	(2,379		)	94			7,457			(1,451		)
Net loss	$	(19,674	)	$	(244,807	)	$	(16,783	)	$	(18,443	)

Loss per share from continuing operations, basic and diluted	$	(0.28	)	$	(3.62	)	$	(0.38	)	$	(0.27	)
Income (loss) per share from discontinued operations, basic and diluted	(0.03		)	—			0.11			(0.02		)
Loss per share, basic and diluted	$	(0.31	)	$	(3.62	)	$	(0.27	)	$	(0.29	)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) accounts_receivable	Dec. 31, 2015 USD ($)
Change in Estimate of the Collectability of Accounts Receivable
Allowance for doubtful accounts, percentage of accounts receivable	28.60%	38.00%
Number of primary overall types of accounts receivable \| accounts_receivable	3
Gross accounts receivable	$ 156,541	$ 157,042
Allowance for doubtful accounts	(44,730)	(59,689)
Net accounts receivable	111,811	97,353
0 - 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	121,590	119,435
Over 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	34,951	37,607
Government
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	28,169	31,313
Government \| 0 - 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	19,891	19,944
Government \| Over 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	8,278	11,369
Commercial
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	117,592	114,690
Commercial \| 0 - 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	97,744	94,477
Commercial \| Over 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	19,848	20,213
Patient
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	10,780	11,039
Patient \| 0 - 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	3,955	5,014
Patient \| Over 180 days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	$ 6,825	$ 6,025

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2016
Computer hardware and software \| Minimum
Property and Equipment
Useful Life	3 years
Computer hardware and software \| Maximum
Property and Equipment
Useful Life	5 years
Office equipment
Property and Equipment
Useful Life	5 years
Vehicles \| Minimum
Property and Equipment
Useful Life	4 years
Vehicles \| Maximum
Property and Equipment
Useful Life	5 years
Medical equipment \| Minimum
Property and Equipment
Useful Life	13 months
Medical equipment \| Maximum
Property and Equipment
Useful Life	5 years
Furniture and fixtures
Property and Equipment
Useful Life	5 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting for Stock-Based Compensation (Details)	Dec. 31, 2016 stock_compensation_plan
Accounting Policies [Abstract]
Number of stock-based employee compensation plans	1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	$ 12,452	$ 15,863
Accounting Standards Update 2015-03 \| Current Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	(3,600)	(3,300)
Accounting Standards Update 2015-03 \| Noncurrent Assets
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	(8,800)	(12,600)
Accounting Standards Update 2015-03 \| Long-term Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred finance costs, net	$ 12,400	$ 15,900

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Common stock, par value (in USD per share)	$ 0.0001				$ 0.0001				$ 0.0001	$ 0.0001
Preferred stock, par value (in USD per share)	$ 0.0001				$ 0.0001				$ 0.0001	$ 0.0001
Loss from continuing operations, net of income taxes									$ (34,367)	$ (303,428)	$ (149,920)
(Loss) income from discontinued operations, net of income taxes	$ (7,273)	$ (174)	$ 75	$ 233	$ (1,451)	$ 7,457	$ 94	$ (2,379)	(7,139)	3,721	2,452
Net loss	$ (12,471)	$ (11,264)	$ (8,234)	$ (9,537)	$ (18,443)	$ (16,783)	$ (244,807)	$ (19,674)	(41,506)	(299,707)	(147,468)
Accrued dividends on Preferred Stock									(8,392)	(6,120)	0
Deemed dividends on Preferred Stock									(692)	(3,690)	0
Loss attributable to common stockholders									$ (50,590)	$ (309,517)	$ (147,468)
Denominator - Basic and Diluted:
Weighted average number of common shares outstanding (in shares)									93,740	68,710	68,476
Loss Per Common Share:
Loss from continuing operations, basic and diluted (in USD per share)	$ (0.06)	$ (0.12)	$ (0.14)	$ (0.17)	$ (0.27)	$ (0.38)	$ (3.62)	$ (0.28)	$ (0.46)	$ (4.56)	$ (2.19)
Income (loss) from discontinued operations, basic and diluted (in USD per share)	(0.06)	0.00	0.00	0.00	(0.02)	0.11	0.00	(0.03)	(0.08)	0.05	0.04
Income (loss) per common share, basic and diluted (in USD per share)	$ (0.12)	$ (0.12)	$ (0.14)	$ (0.17)	$ (0.29)	$ (0.27)	$ (3.62)	$ (0.31)	$ (0.54)	$ (4.51)	$ (2.15)

STOCKHOLDERS' DEFICIT - Securities Purchase Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands				12 Months Ended
	Jul. 31, 2015	May 11, 2015	Mar. 09, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015	Mar. 31, 2010
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)								$ 10.00
Net proceeds used to repay credit facility				$ 64,000	$ 193,663	$ 279,703
Percentage of proceeds used to repay debt				77.00%
Financial instruments:
Series A Preferred Stock			$ 59,355
PIPE Warrants			3,145
Total Investment	$ 1,100		$ 62,500
Revolving Credit Facility \| Credit Facility
Class of Stock [Line Items]
Net proceeds used to repay credit facility				$ 45,300
Class A Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares)	31,025		1,800,000
Price of Warrants (in USD per share)							$ 5.17
Warrants, exercise price (in USD per share)			$ 5.17
Class B Warrants
Class of Stock [Line Items]
Preferred stock offering price (in USD per share)	$ 100
Warrants outstanding (in shares)	31,025		1,800,000
Warrants, exercise price (in USD per share)			$ 6.45				$ 6.45
2015 Warrants
Class of Stock [Line Items]
Proceeds from modification of warrant terms			$ 500
Financial instruments:
Fair value assumptions, volatility (as a percent)			55.00%
Fair value assumptions, risk free interest rate (as a percent)			0.92%
Class A Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)			$ 5.295
Class B Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)			$ 6.595
Series A Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock series, shares issued (in shares)	10,822		625,000
Preferred stock offering price (in USD per share)			$ 100
Price of Warrants (in USD per share)			$ 5.17
Cap on ownership after conversion, percent		19.99%
Financial instruments:
Fair value assumptions, volatility (as a percent)			55.00%
Fair value assumptions, risk free interest rate (as a percent)			0.92%
Fair value assumptions, dividend yield (as a percent)			11.50%

STOCKHOLDERS' DEFICIT - Series A, B, and C Convertible Preferred Stock (Details) $ / shares in Units, $ in Thousands	Jun. 14, 2016 shares	Jun. 10, 2016 shares	Mar. 09, 2015 committee executive $ / shares shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares	Jul. 31, 2015 shares
Class of Stock [Line Items]
Convertible preferred stock series, shares authorized (in shares)			825,000
2015 Warrants \| Common Stock
Class of Stock [Line Items]
Shares reserved (in shares)		3,600,000
Convertible Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock series, shares issued (in shares)			625,000			10,822
Preferred stock offering price (in USD per share) \| $ / shares			$ 100
Fair value assumptions, dividend yield (as a percent)			11.50%
Price of Warrants (in USD per share) \| $ / shares			$ 5.17
Noncumulative cash dividend rate			8.50%
Additional liquidation preference multiple rate			11.50%
Number of committees board members appointed to			5.00%
Number of members holders may elect to board \| executive			1
Voting threshold to elect board members \| committee			2
Series A Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock series, shares authorized (in shares)				825,000	825,000
Convertible preferred stock series, shares issued (in shares)				21,645	635,822
Shares converted (in shares)		614,177
Convertible preferred stock series, shares outstanding (in shares)				21,645	635,822
Convertible preferred stock series, liquidation preference \| $				$ 2,603	$ 69,702
Liquidation preference (in USD per share) \| $ / shares			$ 100.00
Series A Preferred Stock \| 2015 Warrants
Class of Stock [Line Items]
Convertible preferred stock series, shares outstanding (in shares)				10,823
Series B Preferred Stock
Class of Stock [Line Items]
Shares converted (in shares)	614,177
Convertible preferred stock series, shares outstanding (in shares)				0
Series C Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock series, shares authorized (in shares)				625,000
Convertible preferred stock series, shares issued (in shares)				614,177
Convertible preferred stock series, shares outstanding (in shares)				614,177
Convertible preferred stock series, liquidation preference \| $				$ 75,491
Liquidation preference (in USD per share) \| $ / shares			$ 115.48

STOCKHOLDERS' DEFICIT - Carrying Value of Series A and C Preferred Stock (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 09, 2015	Dec. 31, 2016
Convertible Preferred Stock
Class of Stock [Line Items]
Fair value assumptions, dividend yield (as a percent)	11.50%
Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock carrying value, beginning of period		$ 62,918
Exchange of convertible preferred stock		(60,776)
Accretion of discount related to beneficial conversion feature		40
Dividends Recorded		280
Preferred stock carrying value, at end of period		2,462
Series C Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Preferred stock carrying value, beginning of period		0
Exchange of convertible preferred stock		60,776
Accretion of discount related to beneficial conversion feature		652
Dividends Recorded		8,112
Preferred stock carrying value, at end of period		$ 69,540

STOCKHOLDERS' DEFICIT - PIPE Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Mar. 09, 2015	Mar. 31, 2010	Dec. 31, 2016	Jul. 31, 2015	Jun. 30, 2015
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)		$ 10.00
Warrants, exercise term		5 years
Percentage of market price for exercise of warrants (less than)			85.00%
Fair value allocated to PIPE Warrants	$ 3,145
Class A Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares)	1,800,000			31,025
Warrants, exercise price (in USD per share)	$ 5.17
Class B Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares)	1,800,000			31,025
Warrants, exercise price (in USD per share)	$ 6.45				$ 6.45
2015 Warrants
Class of Stock [Line Items]
Proceeds from modification of warrant terms	$ 500
Warrants, exercise term			10 years
Discount related to issuance costs	(203)
Carrying value of PIPE Warrants	$ 2,942
Class A Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)	$ 5.295
Class B Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)	$ 6.595

STOCKHOLDERS' DEFICIT - Rights Offering (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 31, 2015	Mar. 09, 2015	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2015	Mar. 31, 2010
Class of Stock [Line Items]
Preferred stock, par value (in USD per share)			$ 0.0001	$ 0.0001
Warrants, exercise price (in USD per share)						$ 10.00
Proceeds raised from rights offering	$ 1,100	$ 62,500
Class A Warrants
Class of Stock [Line Items]
Price of Warrants (in USD per share)					$ 5.17
Warrants, exercise price (in USD per share)		$ 5.17
Warrants outstanding (in shares)	31,025	1,800,000
Class B Warrants
Class of Stock [Line Items]
Warrants, exercise price (in USD per share)		$ 6.45			6.45
Warrants outstanding (in shares)	31,025	1,800,000
Preferred stock offering price (in USD per share)	$ 100
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in USD per share)					$ 5.17
Price of Warrants (in USD per share)		$ 5.17
Convertible preferred stock series, shares issued (in shares)	10,822	625,000
Preferred stock offering price (in USD per share)		$ 100

STOCKHOLDERS' DEFICIT - Shelf Registration Statement (Details)	May 02, 2016 USD ($)
Stockholders' Equity Attributable to Parent [Abstract]
Amount raised in shelf registration	$ 200,000,000.0

STOCKHOLDERS' DEFICIT - 2016 Equity Offering (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 22, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Net proceeds of public stock offering		$ 83,267
Common Stock
Class of Stock [Line Items]
Net proceeds of public stock offering		$ 4
Common Stock \| Secondary Offering
Class of Stock [Line Items]
Shares issued (in shares)	45,200,000
Stock offering price (in USD per share)	$ 2.00
Net proceeds of public stock offering	$ 83,300
Common Stock \| Over-Allotment Option
Class of Stock [Line Items]
Shares issued (in shares)	5,200,000

STOCKHOLDERS' DEFICIT - Home Solutions Transaction (Details) - Home Solutions - USD ($) $ / shares in Units, $ in Thousands		4 Months Ended
	Sep. 09, 2016	Dec. 31, 2016
Class of Stock [Line Items]
Cash consideration paid	$ 67,500	$ 67,516
Equity issued in acquisition (in shares)	3,750,000
Restricted Stock Units (RSUs) \| Tranche A
Class of Stock [Line Items]
Value of equity issued in acquisition	$ 3,100
Share price of shares issued in acquisition (in USD per share)	$ 4.00
Restricted Stock Units (RSUs) \| Tranche B
Class of Stock [Line Items]
Value of equity issued in acquisition	$ 4,000
Share price of shares issued in acquisition (in USD per share)	$ 5.00

STOCKHOLDERS' DEFICIT - Authorized Shares (Details) - shares	Dec. 31, 2016	Nov. 30, 2016	Dec. 31, 2015
Equity [Abstract]
Common stock, shares authorized (in shares)	250,000,000	125,000,000	125,000,000

STOCKHOLDERS' DEFICIT - Treasury Stock (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stockholders' Equity Attributable to Parent [Abstract]
Treasury stock surrendered to satisfy tax withholding obligations (in shares)	13,570	16,952
Treasury stock held (in shares)	0	2,654,051

STOCKHOLDERS' DEFICIT - Common Stock Purchase Warrants (Details) - $ / shares		1 Months Ended
	Mar. 15, 2015	Mar. 31, 2010
Stockholders' Equity Attributable to Parent [Abstract]
Warrants issued (in shares)		3,400,000
Warrants, exercise term		5 years
Warrants, exercise price (in USD per share)		$ 10.00
Warrants exercised (in shares)	0

ACQUISITIONS - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended								4 Months Ended	12 Months Ended
	Sep. 09, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenue		$ 240,123	$ 224,542	$ 232,462	$ 238,462	$ 243,745	$ 247,224	$ 246,897	$ 244,357		$ 935,589	$ 982,223	$ 922,654
Gross profit		74,650	62,585	64,164	64,232	65,909	65,233	64,818	64,955		265,631	260,915	250,753
Net income		$ (12,471)	$ (11,264)	$ (8,234)	$ (9,537)	$ (18,443)	$ (16,783)	$ (244,807)	$ (19,674)		(41,506)	$ (299,707)	$ (147,468)
Home Solutions
Business Acquisition [Line Items]
Cash consideration paid	$ 67,500									$ 67,516
Equity issued in acquisition (in shares)	3,750,000
Revenue											26,800
Gross profit											9,200
Net income											3,200
Acquisition related expenses											$ 10,100
Home Solutions \| Tranche A \| Restricted Stock Units (RSUs)
Business Acquisition [Line Items]
Value of equity issued in acquisition	$ 3,100
Home Solutions \| Tranche B \| Restricted Stock Units (RSUs)
Business Acquisition [Line Items]
Value of equity issued in acquisition	$ 4,000

ACQUISITIONS - Consideration Transferred in Acquisition (Details) - Home Solutions - USD ($) $ in Thousands		4 Months Ended
	Sep. 09, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Cash	$ 67,500	$ 67,516
Equity issued at closing		9,938
Capital lease obligation assumed		301
Fair value of contingent consideration		15,400
Total consideration		$ 93,155

ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Sep. 09, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 365,947		$ 308,729	$ 573,323
Home Solutions
Business Acquisition [Line Items]
Accounts receivable		$ 11,956
Inventories		3,199
Prepaids and other assets		852
Total current assets		16,007
Property and equipment		4,651
Goodwill		57,218
Other long-term assets		891
Total assets		110,867
Accounts payable		14,576
Accrued liabilities		3,136
Total liabilities		17,712
Net assets acquired		93,155
Home Solutions \| Managed care contracts
Business Acquisition [Line Items]
Intangible assets		24,700
Home Solutions \| Licenses
Business Acquisition [Line Items]
Intangible assets		5,400
Home Solutions \| Trade name
Business Acquisition [Line Items]
Intangible assets		1,800
Home Solutions \| Non-compete agreements
Business Acquisition [Line Items]
Intangible assets		$ 200

ACQUISITIONS - Pro Forma Combined Results (Details) - Home Solutions - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenues	$ 1,019	$ 1,091	$ 1,028
Gross profit	$ 288	$ 289	$ 277
Gross profit percentage	28.30%	26.50%	26.90%
Loss from continuing operations, net of income taxes	$ (44)	$ (322)	$ (178)
Basic loss per share from continuing operations (in USD per share)	$ (0.47)	$ (4.68)	$ (2.60)
Diluted loss per share from continuing operations (in USD per share)	$ (0.47)	$ (4.68)	$ (2.60)

ACQUISITIONS - Acquisition and Integration Expense (Details) - Acquisition and Integration Costs - All Current Acquirees - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Combination, Separately Recognized Transactions [Line Items]
Legal and professional fees	$ 3,059	$ 1,033	$ 6,931
Financial advisory fees	5,087	0	0
Employee costs including redundant salaries and benefits and severance	0	0	2,016
Facilities consolidation and discontinuation	1,323	488	1,401
Bad debt expense and contractual adjustments related to acquired accounts receivable	0	0	5,430
Legal settlement	0	0	334
Other	653	219	1,812
Total	$ 10,122	$ 1,740	$ 17,924

DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($) $ in Thousands				12 Months Ended
	Dec. 28, 2016	Aug. 27, 2015	Mar. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Oct. 20, 2015
Discontinued Operations
Total consideration received		$ 24,600
PBM Services
Discontinued Operations
Reduction in total consideration							$ 1,000
Gain on sale before income taxes				$ 0	$ (11,424)	$ 0
Home Health Business
Discontinued Operations
Gain on sale before income taxes			$ (2,100)	$ 0	$ 0	$ (2,067)
Home Health Business \| Amendment Number One
Discontinued Operations
Total consideration received			59,500
Additional payment received			1,100
Final purchase price received			$ 60,600
Pharmacy Services Asset Sale \| Walgreens \| Arbitration Settled Litigation
Discontinued Operations
Settlement amount accrued	$ 5,800
Total sales claimed in violation of agreement, percentage	3.00%

DISCONTINUED OPERATIONS - Carrying Value of Net Assets (Details) - USD ($) $ in Thousands	Aug. 27, 2015	Mar. 31, 2014
PBM Services
Discontinued Operations
Net accounts receivable	$ 7,163
Total current assets	7,163
Property and equipment, net	175
Goodwill	12,744
Total assets	20,082
Amounts due to plan sponsors	6,950
Total liabilities	6,950
Net assets	$ 13,132
Home Health Business
Discontinued Operations
Net accounts receivable		$ 12,597
Prepaid expenses and other current assets		242
Total current assets		12,839
Property and equipment, net		402
Goodwill		33,784
Intangible assets		15,400
Other non-current assets		28
Total assets		62,453
Accounts payable		673
Amounts due to plan sponsors		229
Accrued expenses and other current liabilities		3,008
Total liabilities		3,910
Net assets		$ 58,543

DISCONTINUED OPERATIONS - Summary of Operating Results (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Discontinued Operations
Bad debt expense		$ 26,799	$ 41,042	$ 79,547
PBM Services
Discontinued Operations
Revenue		0	44,375	61,401
Gross profit		0	9,763	17,635
Other operating expenses		1,015	5,444	10,878
Bad debt expense		0	(45)	27
(Loss) income from operations		(1,015)	4,364	6,730
Gain on sale before income taxes		0	(11,424)	0
Financial advisory fee and legal expenses		614	1,731	0
Other income and expenses, net		(326)	1,898	(6)
Income (loss) before income taxes		(1,303)	12,159	6,736
Income tax expense (benefit)		0	206	198
Income (loss) from discontinued operations, net of income taxes		(1,303)	11,953	6,538
Home Health Business
Discontinued Operations
Revenue		0	0	18,551
Gross profit		0	0	6,918
Other operating expenses		0	417	8,219
Bad debt expense		0	0	902
(Loss) income from operations		0	(417)	(2,203)
Gain on sale before income taxes	$ (2,100)	0	0	(2,067)
Financial advisory fee and legal expenses		(44)	0	2,875
Impairment of assets		0	0	452
Other income and expenses, net		(118)	861	47
Income (loss) before income taxes		162	(1,278)	(3,510)
Income tax expense (benefit)		0	0	(4,257)
Income (loss) from discontinued operations, net of income taxes		162	(1,278)	747
Pharmacy Services Asset Sale
Discontinued Operations
Revenue		0	0	0
Gross profit		0	0	(439)
Other operating expenses		185	4,485	3,995
Financial advisory fee and legal expenses		2	1,312	0
Other income and expenses, net		17	1,157	399
Income (loss) from discontinued operations, net of income taxes		$ (204)	$ (6,954)	$ (4,833)

GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 308,729	$ 573,323
Impairment	0	(251,850)	$ 0
Disposition of PBM Services		(12,744)
Acquisition of Home Solutions	57,218
Goodwill, ending balance	$ 365,947	$ 308,729	$ 573,323

GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Impairment of goodwill	$ 0	$ 251,850	$ 0
Depreciation and amortization expense	$ 6,200	$ 5,100	$ 6,600
Goodwill \| Minimum
Goodwill [Line Items]
Growth rate	3.00%
EBITDA margin	0.06
Discount rate	9.00%
Goodwill \| Maximum
Goodwill [Line Items]
Growth rate	5.00%
EBITDA margin	0.08
Discount rate	11.00%

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite Lived Assets
Gross Carrying Amount	$ 59,250	$ 27,150
Accumulated Amortization	(28,207)	(22,022)
Net Carrying Amount	31,043	5,128
Infusion customer relationships
Finite Lived Assets
Gross Carrying Amount	25,650	25,650
Accumulated Amortization	(23,768)	(20,789)
Net Carrying Amount	1,882	4,861
Managed care contracts
Finite Lived Assets
Gross Carrying Amount	24,700	0
Accumulated Amortization	(1,898)	0
Net Carrying Amount	22,802	0
Licenses
Finite Lived Assets
Gross Carrying Amount	5,400	0
Accumulated Amortization	(906)	0
Net Carrying Amount	4,494	0
Trade name
Finite Lived Assets
Gross Carrying Amount	1,800	0
Accumulated Amortization	(281)	0
Net Carrying Amount	1,519	0
Non-compete agreements
Finite Lived Assets
Gross Carrying Amount	1,700	1,500
Accumulated Amortization	(1,354)	(1,233)
Net Carrying Amount	$ 346	$ 267

GOODWILL AND INTANGIBLE ASSETS - Finite-Lived Intangible Asset Useful Life (Details)	12 Months Ended
	Dec. 31, 2016
Infusion customer relationships \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	5 months
Infusion customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	4 years
Managed care contracts
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	4 years
Licenses
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	2 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	2 years
Non-compete agreements \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	1 year
Non-compete agreements \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	5 years

GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2017	$ 11,925
2018	8,821
2019	6,121
2020	4,176
2021	0
Thereafter	0
Total estimated amortization expense	$ 31,043	$ 5,128

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSE, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Change in fair value of contingent consideration	$ (4,597)	$ (30)	$ (7,364)
Total restructuring, acquisition, integration, and other expenses, net	15,859	24,405	30,206
Financial Improvement Plan
Restructuring Cost and Reserve [Line Items]
Restructuring expense	10,334	22,635	19,646
Acquisition and integration expenses	10,122	1,740	17,924
Change in fair value of contingent consideration	(4,597)	30	(7,364)
Total restructuring, acquisition, integration, and other expenses, net	$ 15,859	$ 24,405	$ 30,206

PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property and Equipment
Property and equipment, gross	$ 107,626,000	$ 93,974,000
Less: Accumulated depreciation	(75,091,000)	(62,035,000)
Property and equipment, net	32,535,000	31,939,000
Depreciation expense	21,551,000	22,743,000	$ 22,943,000
Depreciation related to software capitalized for internal use	2,200,000	2,500,000	2,400,000
Impairment of property, plant and equipment	0
Computer and office equipment
Property and Equipment
Property and equipment, gross	29,556,000	22,561,000
Software capitalized for internal use
Property and Equipment
Property and equipment, gross	16,481,000	15,600,000
Work in progress	5,800,000	1,800,000
Vehicles
Property and Equipment
Property and equipment, gross	2,552,000	1,938,000
Medical equipment
Property and Equipment
Property and equipment, gross	31,509,000	28,423,000
Work in progress
Property and Equipment
Property and equipment, gross	5,746,000	6,624,000
Furniture and fixtures
Property and Equipment
Property and equipment, gross	5,318,000	4,543,000
Leasehold improvements
Property and Equipment
Property and equipment, gross	16,464,000	14,285,000
Assets held under capital leases
Property and Equipment
Depreciation expense	$ 15,400,000	$ 17,600,000	$ 16,400,000

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Feb. 11, 2014
Debt Instrument [Line Items]
Long-term debt	$ 467,716
Less: Deferred financing costs	(12,452)	$ (15,863)
Total Debt	451,934	418,121
Less: Current portion	(18,521)	(24,380)
Long-term debt, net of current portion	433,413	393,741
Term Loan Facilities
Debt Instrument [Line Items]
Long-term debt	210,207	222,757
2021 Notes, net of unamortized discount
Debt Instrument [Line Items]
Long-term debt	196,670	196,038
Less: Deferred financing costs			$ (500)
Capital leases
Debt Instrument [Line Items]
Capital leases	2,209	189
Senior Credit Facilities \| Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt	$ 55,300	$ 15,000

DEBT - Senior Credit Facilities (Details)							12 Months Ended			25 Months Ended
DEBT - Senior Credit Facilities (Details)	Jan. 06, 2017 USD ($)	Mar. 01, 2015 Quarter	Feb. 11, 2014 USD ($)	Jan. 31, 2014 USD ($)	Dec. 23, 2013 USD ($)	Jul. 31, 2013 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jan. 31, 2016 USD ($)	Aug. 06, 2015 USD ($)	Mar. 09, 2015	Mar. 31, 2014 USD ($)
Debt Instrument [Line Items]
Percentage of proceeds to be used to repay debt												75.00%
Net proceeds used to repay credit facility							$ 64,000,000	$ 193,663,000	$ 279,703,000
Amount of debt drawn down							467,716,000
Home Health Business
Debt Instrument [Line Items]
Proceeds from discontinued operation													$ 54,200,000
Civil Action
Debt Instrument [Line Items]
Legal settlement amount					$ 15,000,000					$ 15,000,000
Second Lien Debt \| Second Amendment
Debt Instrument [Line Items]
New debt permitted				$ 150,000,000.0
Unsecured Debt \| Second Amendment
Debt Instrument [Line Items]
New debt permitted				$ 250,000,000.0
Percent of proceeds appropriated to credit facility				100.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Repayments of short-term debt			$ 59,300,000					$ 17,200,000
Repayment of long-term debt							$ 22,700,000
Effective interest rate							8.00%
Remaining borrowing capacity							$ 0
Revolving Credit Facility \| Letter of Credit
Debt Instrument [Line Items]
Long-term line of credit							4,600,000
Revolving Credit Facility \| Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 75,000,000
Net proceeds used to repay credit facility							45,300,000
Periodic payment, principal to be paid quarterly							3,100,000
Periodic payment, balloon payment to be paid							166,300,000
Term Loan B Facility \| Credit Facility
Debt Instrument [Line Items]
Aggregate principal debt amount						250,000,000
Delayed Draw Term Loan B Facility \| Credit Facility
Debt Instrument [Line Items]
Aggregate principal debt amount						$ 150,000,000
Senior Credit Facilities \| Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate, minimum				5.25%
Senior Credit Facilities \| Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate, minimum				4.25%
Senior Credit Facilities \| First Amendment
Debt Instrument [Line Items]
Payments of debt restructuring costs					$ 500,000
Senior Credit Facilities \| Second Amendment \| Eurodollar
Debt Instrument [Line Items]
Basis spread on variable rate				6.00%
Basis spread on variable rate, minimum				5.25%
Senior Credit Facilities \| Second Amendment \| Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate				5.00%
Basis spread on variable rate, minimum				4.25%
Senior Credit Facilities \| Third Amendment
Debt Instrument [Line Items]
Fiscal quarters used in measuring net leverage \| Quarter		4
Senior Credit Facilities \| Fourth Amendment
Debt Instrument [Line Items]
Maximum utilization of borrowing capacity under covenant											$ 60,000,000
Senior Credit Facilities \| Credit Facility
Debt Instrument [Line Items]
Penalty interest rate increase						2.00%
2015 Notes \| Credit Facility
Debt Instrument [Line Items]
Stated interest rate								10.25%
Priming Credit Agreement \| Credit Facility \| Subsequent Event
Debt Instrument [Line Items]
Aggregate principal debt amount	$ 25,000,000
Penalty interest rate increase	2.00%
Stated interest rate	10.00%
2021 Notes
Debt Instrument [Line Items]
Aggregate principal debt amount			$ 200,000,000.0
Stated interest rate			8.875%
Proceeds from issuance of long-term debt			$ 194,500,000
Amount of debt drawn down							$ 196,670,000	$ 196,038,000
Term Loan Facilities
Debt Instrument [Line Items]
Repayments of short-term debt								37,000,000
Early repayment of senior debt			$ 135,200,000
Effective interest rate							6.50%
Amount of debt drawn down							$ 210,207,000	$ 222,757,000

DEBT - 2021 Notes (Details) - USD ($)		12 Months Ended
DEBT - 2021 Notes (Details) - USD ($)	Feb. 11, 2014	Dec. 31, 2015	Dec. 31, 2016
Debt Instrument [Line Items]
Unamortized discount			$ 3,300,000
2021 Notes
Debt Instrument [Line Items]
Aggregate principal debt amount	$ 200,000,000.0
Stated interest rate	8.875%
Unamortized discount	$ 5,000,000
Repurchase price percentage offer	101.00%
Proceeds from issuance of long-term debt	$ 194,500,000
2021 Notes \| Redemption Period One
Debt Instrument [Line Items]
Debt redemption amount, maximum	35.00%
Debt redemption price	108.88%
Revolving Credit Facility
Debt Instrument [Line Items]
Repayments of short-term debt	$ 59,300,000	$ 17,200,000
Term Loan Facilities
Debt Instrument [Line Items]
Repayments of short-term debt		$ 37,000,000
Repayments of long-term debt	$ 135,200,000

DEBT - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt	$ 467,716
Term Loan Facilities
Debt Instrument [Line Items]
Long-term debt	210,207	$ 222,757
2021 Notes
Debt Instrument [Line Items]
Long-term debt	196,670	$ 196,038
Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term debt	406,877
Fair Value \| Fair Value, Inputs, Level 1 \| Term Loan Facilities
Debt Instrument [Line Items]
Long-term debt	0
Fair Value \| Fair Value, Inputs, Level 1 \| 2021 Notes
Debt Instrument [Line Items]
Long-term debt	0
Fair Value \| Fair Value, Inputs, Level 1 \| Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term debt	0
Fair Value \| Fair Value, Inputs, Level 2 \| Term Loan Facilities
Debt Instrument [Line Items]
Long-term debt	195,493
Fair Value \| Fair Value, Inputs, Level 2 \| 2021 Notes
Debt Instrument [Line Items]
Long-term debt	147,502
Fair Value \| Fair Value, Inputs, Level 2 \| Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term debt	342,995
Fair Value \| Fair Value, Inputs, Level 3 \| Term Loan Facilities
Debt Instrument [Line Items]
Long-term debt	0
Fair Value \| Fair Value, Inputs, Level 3 \| 2021 Notes
Debt Instrument [Line Items]
Long-term debt	0
Fair Value \| Fair Value, Inputs, Level 3 \| Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term debt	$ 0

DEBT - Deferred Financing Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Feb. 11, 2014	Jul. 31, 2013
Debt Instrument [Line Items]
Deferred finance costs, net	$ 12,452	$ 15,863
Senior Credit Facilities
Debt Instrument [Line Items]
Deferred finance costs, net				$ 24,600
2021 Notes
Debt Instrument [Line Items]
Deferred finance costs, net			$ 500

DEBT - Future Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Deferred finance costs, net	$ (12,452)	$ (15,863)
Unamortized discount	3,300
2017	22,315
2018	59,599
2019	13,053
2020	172,749
2021	200,000
Thereafter	0
Total future maturities	$ 467,716

DEBT - Interest Expense (Details)	Dec. 31, 2016	Dec. 31, 2015
Credit Facility \| Revolving Credit Facility
Short-term Debt [Line Items]
Weighted average interest rate	10.30%	11.70%

COMMITMENTS AND CONTINGENCIES - Legal Proceedings (Details) $ in Thousands				1 Months Ended	12 Months Ended	25 Months Ended
	Dec. 28, 2016 USD ($)	Oct. 09, 2015 USD ($)	Dec. 23, 2013 USD ($)	Jan. 31, 2016 USD ($)	Dec. 31, 2013 USD ($)	Jan. 31, 2016 USD ($) payment
Legal Proceedings
Payments for legal settlements				$ 6,200
McCormack Shareholder Class Action Litigation
Legal Proceedings
Payments for legal settlements		$ 130
Civil Action
Legal Proceedings
Payments for legal settlements						$ 6,200
Legal settlement amount			$ 15,000			$ 15,000
Interest rate on annual payments						3.25%
Number of annual payments \| payment						3
Fees paid to Relator				$ 200		$ 200
Pharmacy Services Asset Sale \| Civil Action
Legal Proceedings
Legal settlement amount					$ 15,000
Arbitration Settled Litigation \| Pharmacy Services Asset Sale \| Walgreens
Legal Proceedings
Total sales claimed in violation of agreement, percentage	3.00%
Settlement amount accrued	$ 5,800
Percent of total damages sought	20.00%

COMMITMENTS AND CONTINGENCIES - Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating Leases
2017	$ 8,125
2018	5,813
2019	3,371
2020	1,914
2021	593
2022 and Thereafter	577
Total Future Minimum Lease Payments	20,393
Capital Leases
2017	766
2018	749
2019	503
2020	387
2021	0
2022 and Thereafter	0
Total Future Minimum Lease Payments	2,405
Total
2017	8,891
2018	6,562
2019	3,874
2020	2,301
2021	593
2022 and Thereafter	577
Total Future Minimum Lease Payments	22,798
Rent expense for leased facilities and equipment	7,300	$ 7,200	$ 7,600
Purchase commitment	$ 38,000
Minimum
Future minimum lease payment for operating and capital leases
Capital lease interest rate	3.00%
Maximum
Future minimum lease payment for operating and capital leases
Capital lease interest rate	7.00%

CONCENTRATION OF RISK (Details) - Sales Revenue	12 Months Ended
CONCENTRATION OF RISK (Details) - Sales Revenue	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
UnitedHealthcare \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%	26.00%	22.00%
Medicare \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	8.00%	7.00%	11.00%
Immune Globulin \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	19.00%	17.00%	17.00%

INCOME TAXES - Reconciliation of Tax (Benefit) Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal	$ 0	$ 0	$ (886)
State	(30)	(76)	(41)
Total current	(30)	(76)	(927)
Federal	1,744	(18,293)	9,951
State	301	(3,163)	2,169
Total deferred	2,045	(21,456)	12,120
Tax provision (benefit)	$ 2,015	$ (21,532)	$ 11,193

INCOME TAXES - Temporary Differences That Give Rise to Deferred Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Reserves not currently deductible	$ 19,249	$ 27,467
Net operating loss carryforwards	121,084	91,350
Goodwill and intangibles (tax deductible)	27,549	34,983
Accrued expenses	467	654
Property basis differences	2,578	1,021
Stock based compensation	6,887	8,245
Other	638	715
Total deferred tax assets	178,452	164,435
Deferred tax liabilities:
Indefinite-lived goodwill and intangibles	(2,281)	(236)
Less: valuation allowance	(178,452)	(164,435)
Net deferred tax liability	(2,281)	(236)
Deferred taxes	$ (2,281)	$ (236)

INCOME TAXES - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ (178,452)	$ (164,435)
Unrecognized Tax Benefits	1,021	1,067	$ 1,096	$ 1,172
Gross unrecognized tax benefits that would favorably affect effective income tax rate	100
Accrued interest related to uncertain tax positions		$ 100
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	320,600
Net operating loss carryforwards subject to annual limitation	15,600
NOLs to be recorded in additional paid-in capital when realized	(18,200)
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 366,200

INCOME TAXES - Reconciliation of Statutory to Effective Income Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Tax (benefit) at statutory rate	$ (11,275)	$ (113,736)	$ (48,554)
State tax (benefit), net of federal taxes	(1,322)	(8,356)	(3,959)
Valuation allowance changes affecting income tax expense	14,017	57,023	63,641
Change in tax contingencies	(66)	(37)	(109)
Goodwill impairment	0	43,362	0
Other	661	212	174
Tax provision (benefit)	$ 2,015	$ (21,532)	$ 11,193

INCOME TAXES - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 1,067	$ 1,096	$ 1,172
Lapse of statute of limitations	(46)	(29)	(76)
Unrecognized tax benefits, ending balance	$ 1,021	$ 1,067	$ 1,096

STOCK-BASED COMPENSATION - Equity Incentive Plan (Details) - shares	Nov. 30, 2016	May 08, 2014	Dec. 31, 2016
2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)		2,500,000
Number of shares authorized (in shares)		9,355,000
Shares available for grant (in shares)			6,775,475
2016 Additional Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized (in shares)	5,250,000
Number of shares authorized (in shares)	14,605,000

STOCK-BASED COMPENSATION - Employee Stock Purchase Plan (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	May 07, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	319,070		750,000
Common stock, par value (in USD per share)			$ 0.0001
Stock issued during period, (in shares)	245,371
Compensation expense	$ 0.1

STOCK-BASED COMPENSATION - BioScrip/CHS Equity Plan (Details)	Dec. 31, 2016 shares
BioScrip/ CHS Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	0

STOCK-BASED COMPENSATION - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from exercise of employee stock compensation plans	$ (202)	$ (108)	$ 1,100
Unrecognized compensation expense	$ 1,400
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Exercise period	10 years
Compensation expense	$ 3,400	$ 4,800	$ 6,900
Grant date fair value of options (in USD per share)	$ 0.72	$ 2.25	$ 4.32
Net proceeds from exercise of employee stock compensation plans			$ 1,500
Weighted-average period for unrecognized compensation expense	1 year 11 months 28 days
Stock Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (as a percent)	100.00%

STOCK-BASED COMPENSATION - Schedule of Weighted-average Assumptions (Details) - Stock Option	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	68.10%	62.30%	61.00%
Risk-free interest rate	1.98%	2.20%	2.50%
Expected life of options	4 years 9 months 22 days	8 years 9 months 55 days	5 years 8 months 15 days
Dividend rate	0.00%	0.00%	0.00%

STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - Stock Option - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options
Beginning Balance, Options (in shares)	6,635,597
Granted, Options (in shares)	562,810
Exercised, Options (in shares)	0
Forfeited and expired, Options (in shares)	(1,933,037)
Ending Balance, Options (in shares)	5,265,370	6,635,597
Weighted Average Exercise Price
Beginning Balance, Weighted Average Exercise Price (in USD per share)	$ 6.46
Granted, Weighted Average Exercise Price (in USD per share)	1.26
Exercised, Weighted Average Exercise Price (in USD per share)	0.00
Forfeited and expired, Weighted Average Exercise Price (in USD per share)	6.79
Ending Balance, Weighted Average Exercise Price (in USD per share)	$ 5.78	$ 6.46
Aggregate Intrinsic Value	$ 0	$ 1,600
Weighted Average Remaining Contractual Term	4 years 4 months 26 days	5 years 9 months 26 days
Outstanding options less expected forfeitures, Options (in shares)	5,132,477
Outstanding options less expected forfeitures, Weighted Average Exercise Price (in USD per share)	$ 5.85
Outstanding options less expected forfeitures, Aggregate Intrinsic Value	$ 0
Outstanding options less expected forfeitures, Weighted Average Remaining Contractual Life	4 years 3 months 20 days
Exercisable, Options (in shares)	4,035,588
Exercisable, Weighted Average Exercise Price (in USD per share)	$ 6.68
Exercisable, Aggregate Intrinsic Value	$ 0
Exercisable, Weighted Average Remaining Contractual Life	3 years 3 months 20 days

STOCK-BASED COMPENSATION - Schedule of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2016 $ / shares shares
Options Outstanding and Exercisable
Outstanding Options (in shares) \| shares	5,265,370
Weighted Average Exercise Price (in USD per share)	$ 5.78
Weighted Average Remaining Contractual Life	4 years 5 months
Options Exercisable (in shares) \| shares	4,035,588
Weighted Average Exercise Price (in USD per share)	$ 6.68
$0.00 - $2.06
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	0
Maximum range of option exercise price (in USD per share)	$ 2.06
Outstanding Options (in shares) \| shares	552,810
Weighted Average Exercise Price (in USD per share)	$ 1.19
Weighted Average Remaining Contractual Life	6 years 4 days
Options Exercisable (in shares) \| shares	110,000
Weighted Average Exercise Price (in USD per share)	$ 1.53
$2.06 - $4.13
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	2.06
Maximum range of option exercise price (in USD per share)	$ 4.13
Outstanding Options (in shares) \| shares	1,350,984
Weighted Average Exercise Price (in USD per share)	$ 2.67
Weighted Average Remaining Contractual Life	5 years 9 months 4 days
Options Exercisable (in shares) \| shares	801,680
Weighted Average Exercise Price (in USD per share)	$ 2.73
$4.13 - $6.19
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	4.13
Maximum range of option exercise price (in USD per share)	$ 6.19
Outstanding Options (in shares) \| shares	572,000
Weighted Average Exercise Price (in USD per share)	$ 4.84
Weighted Average Remaining Contractual Life	4 years 6 months 75 days
Options Exercisable (in shares) \| shares	464,334
Weighted Average Exercise Price (in USD per share)	$ 4.75
$6.19 - $8.25
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	6.19
Maximum range of option exercise price (in USD per share)	$ 8.25
Outstanding Options (in shares) \| shares	1,898,576
Weighted Average Exercise Price (in USD per share)	$ 7.06
Weighted Average Remaining Contractual Life	3 years 3 months 55 days
Options Exercisable (in shares) \| shares	1,768,574
Weighted Average Exercise Price (in USD per share)	$ 7.01
$8.25 - $10.32
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	8.25
Maximum range of option exercise price (in USD per share)	$ 10.32
Outstanding Options (in shares) \| shares	252,500
Weighted Average Exercise Price (in USD per share)	$ 9.09
Weighted Average Remaining Contractual Life	1 year
Options Exercisable (in shares) \| shares	252,500
Weighted Average Exercise Price (in USD per share)	$ 9.09
$10.32 - $12.38
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	10.32
Maximum range of option exercise price (in USD per share)	$ 12.38
Outstanding Options (in shares) \| shares	305,000
Weighted Average Exercise Price (in USD per share)	$ 11.04
Weighted Average Remaining Contractual Life	5 years
Options Exercisable (in shares) \| shares	305,000
Weighted Average Exercise Price (in USD per share)	$ 11.04
$12.38 - $14.41
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	12.38
Maximum range of option exercise price (in USD per share)	$ 14.41
Outstanding Options (in shares) \| shares	325,500
Weighted Average Exercise Price (in USD per share)	$ 12.92
Weighted Average Remaining Contractual Life	2 years 10 months 9 days
Options Exercisable (in shares) \| shares	325,500
Weighted Average Exercise Price (in USD per share)	$ 12.92
$16.50 - $18.57
Options Outstanding and Exercisable
Minimum range of option exercise price (in USD per share)	16.50
Maximum range of option exercise price (in USD per share)	$ 18.57
Outstanding Options (in shares) \| shares	8,000
Weighted Average Exercise Price (in USD per share)	$ 16.63
Weighted Average Remaining Contractual Life	6 years 5 months 67 days
Options Exercisable (in shares) \| shares	8,000
Weighted Average Exercise Price (in USD per share)	$ 16.63

STOCK-BASED COMPENSATION - Restricted Stock (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense	$ 0.5	$ 0.4	$ 1.6
Unrecognized compensation expense	0.5
Grant date fair value of awards vested	0.9	0.2	3.5
Fair value of awards vested	$ 0.2	$ 0.5	$ 2.0
2008 Plan \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
2008 Plan \| Performance Shares \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Key Employees \| 2008 Plan \| Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Director \| 2008 Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

STOCK-BASED COMPENSATION - Schedule of Restricted Stock Awards (Details) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Restricted Stock Shares
Beginning balance (in shares)	49,998
Granted (in shares)	575,858
Awards Vested (in shares)	(78,500)
Canceled (in shares)	0
Ending balance (in shares)	547,356	49,998
Weighted Average Award Grant Date Fair Value
Beginning balance (in USD per share)	$ 11.89
Granted (in USD per share)	1.63
Awards Vested (in USD per share)	2.59
Canceled (in USD per share)	0.00
Ending balance (in USD per share)	$ 2.43	$ 11.89
Weighted Average Remaining Recognition Period
Weighted average remaining recognition period	2 years 2 months 12 days	2 years 2 months 12 days

STOCK-BASED COMPENSATION - Performance Units (Details) - Key Employees - 2008 Plan - Performance Shares	12 Months Ended
	Dec. 31, 2016 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum annual cash award \| $	$ 1,000,000.0
Grants since inception of plan (in shares) \| shares	377,358

STOCK-BASED COMPENSATION - Stock Appreciation Rights (Details) - Stock Appreciation Rights (SARs) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock appreciation rights (in shares)	300,000	300,000
Vesting period	3 years
Exercise period	10 years
Compensation benefit	$ (100,000)	$ (900,000)
PIPE transaction issuance costs	$ 0	$ 0	$ 0
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Holding period	1 year

STOCK-BASED COMPENSATION - Schedule of SAR Activity (Details) - Stock Appreciation Rights (SARs) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Stock Appreciation Rights
Beginning balance (in shares)	300,000
Granted (in shares)	0
Exercised (in shares)	0
Canceled (in shares)	0
Ending balance (in shares)	300,000	300,000
Weighted Average Exercise Price
Beginning balance (in USD per share)	$ 6.48
Granted (in USD per share)	0.00
Exercised (in USD per share)	0.00
Canceled (in USD per share)	0.00
Ending balance (in USD per share)	$ 6.48	$ 6.48
Weighted Average Remaining Recognition Period
Weighted average remaining recognition period	1 day	1 day

DEFINED CONTRIBUTION PLAN (Details) - USD ($) $ in Millions	12 Months Ended
DEFINED CONTRIBUTION PLAN (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Maximum annual deferral (as a percent)	100.00%
Matching contributions		$ 1.3	$ 1.6

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Selected Quarterly Financial Information [Abstract]
Revenue	$ 240,123	$ 224,542	$ 232,462	$ 238,462	$ 243,745	$ 247,224	$ 246,897	$ 244,357	$ 935,589	$ 982,223	$ 922,654
Gross profit	74,650	62,585	64,164	64,232	65,909	65,233	64,818	64,955	265,631	260,915	250,753
Loss from continuing operations, before income taxes	(3,776)	(10,669)	(8,160)	(9,747)	(15,980)	(28,791)	(264,822)	(15,367)	(32,352)	(324,960)	(138,727)
(Loss) income from discontinued operations, net of income taxes	(7,273)	(174)	75	233	(1,451)	7,457	94	(2,379)	(7,139)	3,721	2,452
Net loss	$ (12,471)	$ (11,264)	$ (8,234)	$ (9,537)	$ (18,443)	$ (16,783)	$ (244,807)	$ (19,674)	$ (41,506)	$ (299,707)	$ (147,468)
Loss from continuing operations, basic and diluted (in USD per share)	$ (0.06)	$ (0.12)	$ (0.14)	$ (0.17)	$ (0.27)	$ (0.38)	$ (3.62)	$ (0.28)	$ (0.46)	$ (4.56)	$ (2.19)
Income (loss) from discontinued operations, basic and diluted (in USD per share)	(0.06)	0.00	0.00	0.00	(0.02)	0.11	0.00	(0.03)	(0.08)	0.05	0.04
Net loss, basic and diluted (in USD per share)	$ (0.12)	$ (0.12)	$ (0.14)	$ (0.17)	$ (0.29)	$ (0.27)	$ (3.62)	$ (0.31)	$ (0.54)	$ (4.51)	$ (2.15)

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

SUBSEQUENT EVENTS (Details) - USD ($)			12 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($)	Mar. 01, 2017	Jan. 06, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Net proceeds in private placement			$ 83,267,000
Common Stock
Subsequent Event [Line Items]
Net proceeds in private placement			$ 4,000
Subsequent Event \| Common Stock \| Private Placement
Subsequent Event [Line Items]
Shares issued (in shares)	3,300,000
Net proceeds in private placement	$ 5,100,000
Stock offering price (in USD per share)	$ 1.5366
Credit Facility \| Priming Credit Agreement \| Subsequent Event
Subsequent Event [Line Items]
Aggregate principal debt amount		$ 25,000,000
Stated interest rate		10.00%
Penalty interest rate increase		2.00%

Schedule II -- Valuation and Qualifying Accounts (Details) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 59,689	$ 66,405	$ 17,735
Write-Off of Receivables	(41,758)	(47,758)	(30,877)
Charged to Costs and Expenses	26,799	41,042	79,547
Balance at End of Period	$ 44,730	$ 59,689	$ 66,405